WO2005013885A2 - Pharmaceutical compositions and methods for accelerating wound healing - Google Patents

Pharmaceutical compositions and methods for accelerating wound healing Download PDF

Info

Publication number
WO2005013885A2
WO2005013885A2 PCT/IL2004/000727 IL2004000727W WO2005013885A2 WO 2005013885 A2 WO2005013885 A2 WO 2005013885A2 IL 2004000727 W IL2004000727 W IL 2004000727W WO 2005013885 A2 WO2005013885 A2 WO 2005013885A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
wound
skin wound
adipocytes
accelerating
Prior art date
Application number
PCT/IL2004/000727
Other languages
French (fr)
Other versions
WO2005013885A3 (en
Inventor
Liora Braiman-Wiksman
Innesa Solomonik
Original Assignee
Healor Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK04745067.1T priority Critical patent/DK1651161T3/en
Priority to NZ545086A priority patent/NZ545086A/en
Priority to AU2004263009A priority patent/AU2004263009B2/en
Application filed by Healor Ltd. filed Critical Healor Ltd.
Priority to JP2006522494A priority patent/JP4668902B2/en
Priority to AT04745067T priority patent/ATE529125T1/en
Priority to CN200480029538XA priority patent/CN101287483B/en
Priority to EP04745067A priority patent/EP1651161B1/en
Priority to ES04745067T priority patent/ES2375565T3/en
Priority to CA2535029A priority patent/CA2535029C/en
Publication of WO2005013885A2 publication Critical patent/WO2005013885A2/en
Priority to IL173596A priority patent/IL173596A0/en
Priority to US11/348,527 priority patent/US7638484B2/en
Priority to HK06111955.4A priority patent/HK1091400A1/en
Priority to US12/009,567 priority patent/US20080159978A1/en
Publication of WO2005013885A3 publication Critical patent/WO2005013885A3/en
Priority to US13/224,311 priority patent/US8507431B2/en
Priority to US13/924,929 priority patent/US20140148389A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to methods and pharmaceutical compositions for accelerating the healing process of wounds.
  • the present invention utilizes bioactive molecules which are secreted by adipocytes (adipokines), and bioactive molecules which regulate adipocytes differentiation, proliferation and/or activity, for inducing or accelerating the healing process of skin wounds.
  • adipokines adipocytes
  • bioactive molecules which regulate adipocytes differentiation, proliferation and/or activity for inducing or accelerating the healing process of skin wounds.
  • Open cutaneous wounds represent one major category of wounds and include burn wounds, neuropathic ulcers, pressure sores, venous stasis ulcers, and diabetic ulcers.
  • Open cutaneous wounds routinely heal by a process which comprises six major components: (i) inflammation; (ii) fibroblast proliferation; (iii) blood vessel proliferation; (iv) connective tissue synthesis; (v) epithelialization; and (vi) wound contraction. Wound healing is impaired when these components, either individually or as a whole, do not function properly. Numerous factors can affect wound healing, including malnutrition, infection, pharmacological agents (e.g., actinomycin and steroids), advanced age and diabetes [see Hunt and Goodson in Current Surgical Diagnosis & Treatment (Way; Appleton & Lange), pp. 86-98 (1988)]. There is also a common problem of wound healing following surgical procedures in various parts of the body, the surgery succeeds but the opening wound fails to heal.
  • pharmacological agents e.g., actinomycin and steroids
  • Skin is a stratified squamous epithelium in which cells undergoing growth and differentiation are strictly compartmentalized. In the physiologic state, proliferation is confined to the basal cells that adhere to the basement membrane. Differentiation is a spatial process where basal cells lose their adhesion to the basement membrane, cease DNA synthesis and undergo a series of morphological and biochemical changes. The ultimate maturation step is the production of the cornified layer forming the protective barrier of the skin (1, 2). The earliest changes observed when basal cells commit to differentiate is associated with the ability of the basal cells to detach and migrate away from the basement membrane (3). Similar changes are associated with the wound healing process where cells both migrate into the wound area and proliferative capacity is enhanced. These processes are mandatory for the restructuring of the skin layers and induction of proper differentiation of the epidermal layers.
  • keratinocytes In vitro, keratinocytes can be maintained as basal proliferating cells with a high growth rate. Furthermore, differentiation can be induced in vitro following the maturation pattern in the epidermis in vivo. The early events include loss of hemidesmosome components (3, 5) and a selective loss of the ⁇ 6 ⁇ 4 integrin and cell attachment to matrix proteins. This suggests that changes in integrin expression are early events in keratinocyte differentiation.
  • the early loss of hemidesmosomal contact leads to suprabasal migration of keratinocytes and is linked to induction of Keratin 1 (Kl) in cultured keratinocytes and in skin (1, 3, 6). Further differentiation to the granular layer phenotype is associated with down regulation of both ⁇ l and ⁇ 4 integrin expression, loss of adhesion potential to all matrix proteins and is followed by cornified envelope formation and cell death. Differentiating cells ultimately sloughs from the culture dish as mature squames (2, 7). This program of differentiation in vitro closely follows the maturation pattern of epidermis in vivo.
  • Wound healing may be induced in vivo by various bioactive agents which directly or indirectly promote growth, differentiation and/or migration of epidermal cells.
  • U.S. Pat. Nos. 5,591,709 and 5,461,030 describe the use of non-steroidal anabolic hormone such as insulin, growth hormone, triiodothyronine and thyroxine for inducing wound closure.
  • U.S. Pat. No. 5,145,679 describes the use of insulin and pancreatin for inducing wound closure.
  • U.S. Pat. No. 6,541,447 describes the use of a mixture of growth factors and growth hormones for inducing wound closure, and International Application No.
  • PCT/ILO 1/00675 describes the use of PKC modulating agents for inducing wound closure.
  • adipocytes adipocyte modulators, or molecules secreted by adipocytes, for inducing or accelerating the processes associated with wound healing.
  • the present invention provides a novel approach for treating wounds by utilizing adipocytes, cells capable of differentiating into adipocytes, products secreted by adipocytes and adipocyte modulators, for inducing or accelerating the processes associated with wound healing.
  • adipocytes are closely associated with migrating keratinocytes at the wound gap during an early stage of the healing process, indicating that adipocytes, adipocyte modulators and adipokines are involved in, and hence may be used to influence, the wound healing process.
  • a method of inducing or accelerating a healing process of a skin wound comprising administering to the skin wound a therapeutically effective amount of an adipokine, thereby inducing or accelerating the healing process of the skin wound.
  • a method of inducing or accelerating a healing process of a skin wound comprising administering to the skin wound a therapeutically effective amount of an agent capable of modulating expression and/or secretion of an adipokine, thereby inducing or accelerating the healing process of the skin wound.
  • a method of inducing or accelerating a healing process of a skin wound comprising administering to the skin wound a therapeutically effective amount of an agent capable of modulating differentiation of adipocytes, thereby inducing or accelerating the healing process of the skin wound.
  • a method of inducing or accelerating a healing process of a skin wound comprising administering to the skin wound a therapeutically effective amount of an agent capable of attracting adipocytes to the skin wound, thereby inducing or accelerating the healing process of the skin wound.
  • a method of inducing or accelerating a healing process of a skin wound comprising administering to the skin wound a therapeutically effective amount of an agent capable of enhancing proliferation of adipocytes in the skin wound, thereby inducing or accelerating the healing process of the skin wound.
  • a method of inducing or accelerating a healing process of a skin wound comprising implanting into the skin wound a therapeutically effective amount of adipocytes, so as to induce or accelerate the healing process of the skin wound.
  • a method of inducing or accelerating a healing process of a skin wound comprising implanting into the skin wound a therapeutically effective amount of preadipocytes, thereby inducing or accelerating the healing process of the skin wound.
  • a method of inducing or accelerating a healing process of a skin wound comprising implanting into the skin wound a therapeutically effective amount of stem cells, thereby inducing or accelerating the healing process of the skin wound.
  • a method of inducing or accelerating a healing process of a skin wound comprising fransforming cells of the skin wound to express and secrete an adipokine, thereby inducing or accelerating the healing process of the skin wound.
  • a pharmaceutical composition for inducing or accelerating a healing process of a skin wound comprising, as an active ingredient, a therapeutically effective amount of an adipokine, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
  • a pharmaceutical composition for inducing or accelerating a healing process of a skin wound comprising, as an active ingredient, a therapeutically effective amount of an agent capable of modulating expression and/or secretion of an adipokine, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
  • a pharmaceutical composition for inducing or accelerating a healing process of a skin wound comprising, as an active ingredient, a therapeutically effective amount of an agent capable of modulating differentiation of adipocytes, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
  • a pharmaceutical composition for inducing or accelerating a healing process of a skin wound comprising, as an active ingredient, a therapeutically effective amount of an agent capable of attracting adipocytes to the skin- wound, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
  • a pharmaceutical composition for inducing or accelerating a healing process of a skin wound comprising, as an active ingredient, a therapeutically effective amount of an agent capable of enhancing proliferation of adipocytes, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
  • a method of determining a capacity of an adipokine or an adipocyte modulator to induce or accelerate a healing process of a wound comprising administering the adipokine or the adipocyte modulator to the wound, and evaluating the wound for a keratinocytes migration and/or an epidermal closure, to thereby determine the capacity of the adipokine or the adipocyte modulator to induce or accelerate healing of wounds.
  • the adipokine is selected from the group consisting of adipsin, adiponectin, resistin, leptin, lipoprotein lipase, angiotensinogen, angiotesin-like 4, 1- Butyrylglycerol, matrix metalloproteinase 2, matrix metalloproteinase 9, vascular endothelial growth factor, interleukin 6, and tumor necrosis factor ⁇ .
  • the adipokine is adipsin
  • the adipocytes modulating agent is a PPAR regulator, preferably a PPAR- ⁇ antagonist, more preferably GW9662.
  • the adipocytes are human adipocytes.
  • the preadipocytes are human preadipocytes.
  • the stem cells are human stem cells.
  • autologous human stem cells Preferably, autologous human stem cells.
  • implanting further includes modulating expression and/or secretion of an adipokine.
  • modulating is effected by differentiation.
  • differentiation is effected by exposing the preadipocytes to a substance capable of enhancing differentiation of the preadipocytes into adipocytes.
  • promoting differentiation is effected by exposing the stem cells to a substance capable of enhancing differentiation of the stem cells into adipocytes.
  • the wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
  • the pharmaceutical composition carrier is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
  • the pharmaceutical composition includes a solid support.
  • the adipocytes modulator is an adipocyte differentiation modulator or an adipocyte activity modulator.
  • the wound is an incision wound which is effected in an experimental animal.
  • the administrating of an adipokine or an adipocyte modulator is effected in one or more concentrations.
  • the administrating of an adipokine or an adipocyte modulator is effected in one or more applications.
  • the present invention provides novel pharmaceutical compositions and methods for treating wounds utilizing adipocytes, cells capable of differentiating into adipocytes, adipocytes modulators and molecules secreted by adipocytes, for inducing or accelerating wound healing.
  • FIG. 1 illustrates the effect of insulin on adipocytes recruitment and epidermal cells migration at the wound area.
  • Wounds were effected on the back of C57BL mice by incision. The wounds were treated daily with topical application of healing- inducing insulin (1 ⁇ M) for six days, then the mice were sacrificed and their wounds analyzed for epidermal cells migration and adipocytes recruitment. Epidermal cell migration was determined by K14 antibody staining and was considered positive if the wound was stained positive across the entire wound gap. Adipocytes recruitment was determined by H&E staining and was considered positive if adipocytes were detected inside the granulation tissue. The dark bars represent the insulin treatment and the light bars represent the buffer-treated control. The results are presented as percent of closed (positive) wounds and each bar represents the mean of six replications ⁇ standard error.
  • FIGs. 2A-B are histochemical micrographs illustrating the association of adipocytes with the wound healing process. Wounds were effected on the back of C57BL mice by incision. The mice were sacrificed seven days after wounding, then sectioned and stained with K14 antibody to highlight migrating epidermal cells. The micrographs show that recruited adipocytes are present at the wound gap in abundance during an early stage of the wound healing process ( Figure 2A, x20 magnification; Figure 2B, xlO magnification).
  • FIG. 3 illustrates the effect of a PPAR ⁇ antagonist (GW9662) on primary keratinocytes migration in vitro.
  • Cultured keratinocytes were either untreated (control), or treated with 2 ⁇ M GW9662.
  • the keratinocytes migration was observed under a light microscope.
  • the upper panels show micrographs of pre-treated (Day 0) cultures, and the bottom left and panels show the resulting control and treated cultures, respectively (Day 2).
  • the blue lines mark the edges of migrating keratinocytes and the arrows point out the enhanced migration of GW9662 treated cultures, as compared with the untreated control.
  • FIG. 4 is a graph illustrating the effects of a PPAR ⁇ antagonist (GW9662) and adipsin on wound healing in vivo. Wounds were effected on the back of C57BL mice by incision and the wounds were then measured (Day 0). The wounds areas treated daily with topical application of PBS (control), adipsin, or GW9662 2 ⁇ M for six days. Mice were then sacrificed and their wound areas were measured (Day 6). The portion of the wound area contracted in the six days from the initial wound area was calculated (% wound contraction) for each treatment. The graph shows that both
  • GW9662 and adipsin promoted a substantial wound contraction, as compared with the buffer-treated control.
  • FIG. 5 is a histochemical micrograph illustrating the effects of a PPAR ⁇ antagonist (GW9662) and adipsin on wound closure in vivo. Wounds were effected on the back of C57BL mice by incision and their area were then measured (Day 0). The wounds were treated daily, for six days, with topical application of PBS (control), adipsin 1 ⁇ M, or GW9662 2 ⁇ M. The mice were then sacrificed, their wounds were fixed with paraformaldehyde and observed under a binocular microscope at x5 magnification. The micrograph shows that the areas of wounds which were treated with GW9662, or with adipsin, are substantially smaller than the wound area of the buffer control.
  • FIG. 5 is a histochemical micrograph illustrating the effects of a PPAR ⁇ antagonist (GW9662) and adipsin on wound closure in vivo. Wounds were effected on the back of C57BL mice by incision and their area were
  • FIG. 6 illustrates the effect of adipsin on epidermal cell migration and wound closure.
  • Wounds were effected on the back of C57BL mice by incision.
  • the wounds were treated daily with topical application of 1 ⁇ M adipsin for seven days, then sacrificed, sectioned and analyzed for epidermal closure and migration by K14 antibody staining.
  • Epidermal closure was considered positive if the wound was stained positive through the entire wound gap.
  • Epidermal migrating was considered positive if the wound was stained positive but not entirely across the wound gap.
  • the bar graph shows that both epidermal closure and epidermal migration were markedly enhanced by adipsin. Each bar represents the mean of six replications.
  • FIG. 7 is a histochemical micrograph illustrating the effects of a PPAR ⁇ antagonist (GW9662) and adipsin on wound closure (contraction). Wounds were effected on the back of C57BL mice by incision and were treated daily, for 6 days, with adipsin (l ⁇ M), GW9662 (2 ⁇ M), or untreated (control). The treated mice were sacrificed six days after wounding. Histochemical wound sections were performed, stained with H&E (upper panel) or with K14 antibody (lower panel), and observed under a light microscope at x5 magnification. The contraction was considered positive if both dermal wound sides (marked by black lines) could be observed in a single field.
  • GW9662 PPAR ⁇ antagonist
  • the opened wound area in the untreated control section (right) was too large to be contained in a single field (thus considered a negative dermal contraction), while the adipsin treated section (left) and the GW9662 treated section (center) show positive dermal contractions.
  • FIG. 8 illustrates the effect of a PPAR ⁇ agonist (froglitazone) on primary keratinocytes migration in vitro.
  • Cultured keratinocytes were either untreated (confrol), or treated with 100 ⁇ M froglitazone, and their migration was observed under a light microscope.
  • the upper panels show micrographs of pre-treated cultures, and the bottom left and right panels show the resulting confrol and treated cultures, respectively (within 48 hours).
  • the lines mark the edges of cultured keratinocytes and indicate a substantially inhibited migration of cultured keratinocytes treated with froglitazone, as compared with the untreated control.
  • FIG. 9 is a histochemical micrograph illustrating the effects of insulin and a PPAR ⁇ agonist (froglitazone) on wound closure in vivo.
  • Wounds were effected on the back of C57BL mice by incision and were treated daily, for 6 days, with topical application of PBS (confrol), insulin (10 nM), froglitazone (100 ⁇ M), or froglitazone (100 ⁇ M) + insulin (10 nM) combined.
  • the mice were then sacrificed, their wounds were fixed with paraformaldehyde and observed under a binocular microscope at x5 magnification.
  • the micrograph shows that the insulin-treated wound area is substantially smaller than the buffer confrol, while the froglitazone and the froglitazone + insulin treated wounds are substantially larger than the buffer confrol.
  • FIG. 10 illustrates the effect of insulin and a PPAR ⁇ agonist (froglitazone) on wound closure incidence.
  • Wounds were effected on the back of C57BL mice by incision. The wounds were treated daily with topical application of PBS (confrol), insulin (10 nM), troglitazone (100 ⁇ M), or troglitazone (100 ⁇ M) + insulin (10 nM) for six days, then sacrificed, sectioned and analyzed for wound closure. The wound closure was determined by K14 and Kl antibody staining. Wound closure was considered positive if the wound was stained positive throughout the entire wound gap. Each bar represents the mean of six replications.
  • the present invention is of methods and pharmaceutical compositions for accelerating the healing process of wounds.
  • the present invention utilizes adipocytes, cells capable of differentiating into adipocytes, bioactive molecules secreted by adipocytes (adipokines) and adipocyte modulators, for accelerating the healing process of skin wounds.
  • adipocytes cells capable of differentiating into adipocytes
  • bioactive molecules secreted by adipocytes adipokines
  • adipocyte modulators for accelerating the healing process of skin wounds.
  • keratinocytes Following keratinocyte migration, keratinocytes enter a proliferative boost, which allows replacement of cells lost during wound formation. After the wound is covered by a monolayer of keratinocytes (i.e., epidermal closure) new stratified epidermis is formed and the new basement membrane is reestablished (8-11). While conducting experiments in wound healing research, the inventors unexpectedly uncovered that adipocytes are closely associated with migrating keratinocytes at the wound area, during an early stage of the wound healing process. Accordingly, Example 1 of the Examples section that follows illustrates that the appearance of migrating keratinocytes at the wound gap was directly correlated with appearance of recruited adipocytes at the same area.
  • adipocytes secrete a number of bioactive molecules, known as adipokines, which play a role in the maintenance of energy homeostasis by regulating insulin secretion, insulin action, glucose and lipid metabolism, energy balance, inflammation, and reproduction.
  • adipokine substantially accelerated keratinocytes migration in vitro and effectively promoted healing of skin wounds in vivo (see in Example 3 of the Examples section which follows).
  • a method of inducing or accelerating a healing process of a skin wound comprising administering to the skin wound a therapeutically effective amount of an adipokine, thereby inducing or accelerating the healing process of the skin wound.
  • wound refers broadly to injuries to the skin and subcutaneous tissue initiated in any one of a variety of ways (e.g., pressure sores from extended bed rest, wounds induced by trauma, cuts, ulcers, burns, surgical incisions and the like) and with varying characteristics.
  • Wounds are typically classified into one of four grades depending on the depth of the wound: (i) Grade I: wounds limited to the epithelium; (ii) Grade II: wounds extending into the dermis; (iii) Grade HI: wounds extending into the subcutaneous tissue; and (iv) Grade IV (or full-thickness wounds): wounds wherein bones are exposed (e.g., a bony pressure point such as the greater frochanter or the sacrum).
  • the term "partial thickness wound” used herein refers to wounds that encompass Grades I-HI; examples of partial thickness wounds include burn wounds, pressure sores, venous stasis ulcers, and diabetic ulcers.
  • deep wound used herein is meant to include both Grade HI and
  • chronic wound used herein refers to a wound that has not healed within thirty days.
  • heating in respect to a wound refers to a process to repair a wound as by scar formation.
  • the present invention contemplates treating all wound types, including deep wounds and chronic wounds.
  • adipokine refers to any bioactive molecule which is secreted by adipocytes in vivo or in vitro, including, but not limited to, adipocyte- secreted enzymes, growth factors, cytokines and hormones.
  • the adipokine of the present invention is selected from the group consisting of complement factors D
  • adipsin C3 and B; vascular endothelial growth factor (VGEF), Adiponectin
  • adipokine is adipsin.
  • adipocytes modulator refers to any molecule capable of modulating expression and/or secretion of adipokines from adipocytes, adipocytes differentiation, adipocytes proliferation, adipocytes migration or attracting adipocytes to the wound gap.
  • Adipocytes are differentiated from preadipocytes in a process known as adipogenesis.
  • adipogenesis is fully dependent on insulin, dexamethasone and isobuthylmethylxanthine, stressing the involvement of insulin, glucocorticoid and cAMP pathways.
  • the key transcriptional factors involved in the adipogenic process include proteins belonging to the CCAAT/enhancer binding protein family, adipocyte determination and differentiation dependent factor 1 (also known as sterol regulatory element - binding protein 1), and peroxisome proliferators-activator receptor ⁇
  • the peroxisome proliferator-activated receptors comprise three types,
  • PPAR ⁇ PPAR ⁇
  • PPAR ⁇ PPAR ⁇
  • PPAR ⁇ PPAR ⁇
  • PPAR ⁇ PPAR ⁇
  • PPAR ⁇ PPAR ⁇
  • PPAR ⁇ PPAR ⁇
  • PPAR ⁇ PPAR ⁇ plays a crucial role in the terminal differentiation by transactivation of adipocyte-specific genes. Recent results suggest a cross talk between PPARs and the cholesterol metabolism pathway in the epidermis.
  • PPAR ⁇ All PPAR isoforms are expressed in embryonic and mature skin. PPAR ⁇ expression dramatically increases at the late stages of fetal maturation. In postnatals, as well as in adult skin, the expression of PPAR ⁇ is decreased. An important role has been suggested for PPAR ⁇ and PPAR ⁇ in keratinocyte differentiation during epidermis formation (Wabli W., Swiss Med. Wkly. 132: 83-91, 2002). It has been also demonstrated that PPAR ⁇ and PPAR ⁇ are up-regulated at the edges of wounded skin and that null mice of these isoformes are wound healing impaired (Michalnik et al., J. Cell Biol. 154: 799-814, 2001). Yet, the involvement of PPAR ⁇ in the wound healing process has not been described nor suggested in the prior art.
  • U.S. Pat. No. 6,403,656 describes the use PPAR ⁇ activators for treating skin disorders related to an anomaly of the differentiation of epidermic cells.
  • International Application No. PCT/US99/28101 describes the use of PPAR ⁇ activators, such as a prostaglandin J2 or D2, for treating obesity and diabetes.
  • PPAR ⁇ activators such as a prostaglandin J2 or D2
  • none of these disclosures teaches or suggests using PPAR ⁇ activators, or inhibitors, for use in healing wounds.
  • Example 2 of the Examples section which follows illustrates that administering troglitazone, a PPAR ⁇ agonist, inhibited wound confraction.
  • administering GW9662 which is a PPAR ⁇ antagonist, promoted wound confraction.
  • a method of inducing or accelerating a healing process of a skin wound comprising administering to the skin wound a therapeutically effective amount of an agent capable of modulating differentiation of adipocytes, thereby inducing or accelerating the healing process of the skin wound.
  • the agent according to this aspect of the present invention may be any agonist or antagonist of any factor, such as a transcriptional factor which is involved in adipocytes differentiation, including, but not limited to, a protein belonging to the CCAAT/enhancer binding protein family, adipocyte determination and differentiation dependent factor 1, and PPAR ⁇ .
  • a transcriptional factor which is involved in adipocytes differentiation including, but not limited to, a protein belonging to the CCAAT/enhancer binding protein family, adipocyte determination and differentiation dependent factor 1, and PPAR ⁇ .
  • the agent is a PPAR- ⁇ antagonist, more preferably GW9662.
  • a healing process of a skin wound can be induced or accelerated by adrninistering to the skin wound a therapeutically effective amount of an agent which is capable of: (i) modulating expression and/or secretion of an adipokine from adipocytes, (ii) enhancing adipocytes proliferation, (ii) enhancing adipocytes migration, or (iii) attracting adipocytes to the wound area.
  • the capacity of an adipokine or an adipocytes modulator to induce or accelerate a healing process of a skin wound can be determined by administering the adipokine or the adipocytes modulator in question to a skin wound and evaluating the treated wounds for keratinocytes migration and/or epidermal closure.
  • the skin wound is effected on the backs of a C57BL mouse by incision and freated with one or more applications, each with one or more concentrations of the adipokine.
  • a desired time period post wounding preferably about 6 days, the mouse is sacrificed and wound biopsies are sampled.
  • the wound biopsies are then analyzed for keratinocytes migration to the wound gap and/or for epidermal closure of the wound gap, using methods known in the art, preferably using the procedures as described in the Examples section that follows.
  • adipocytes preferably autologous adipocytes
  • Adipocytes may be obtained from an adipose tissue of any animal source, preferably from a human donor, most preferably from an autologous human source.
  • the adipose tissue may be sampled from a subcutaneous or perirenal site, preferably subcutaneous, using well recognized protocols such as surgical, suction, liposuction, penniculectomy, or via biopsy.
  • the adipocyte cells are preferably separated from the adipose tissue sample by using enzymes which destroy physical cell contacts (e.g., collagenases), or by using mechanical agitation, sonic or ultrasonic energy and the like.
  • the separated adipocytes can be cultured using suitable tissue culture techniques known in the art such as, for example, described in details in International Application PCT/US00/30623.
  • the cultured adipocytes are allowed to grow until near-confluence is reached, then removed by gentle scrapping from the growth medium and implanted onto the wound.
  • preadipocytes can also be generated from cultured preadipocytes.
  • preadipocyte refers to any cell which is capable of differentiating into an adipocyte.
  • preadipocytes are human adipocytes, more preferably autologous adipocytes isolated from the patient's own adipose or other tissue.
  • the adipose tissue may be sampled from subcutaneous or perirenal sites using well recognized protocols such as surgical, suction liposuction, penniculectomy, or via biopsy.
  • the preadipocyte cells may be isolated from the sampled tissue by using methods such as described by Rodbell et al. (Meth. Enzymol. 31:103-114, 1974).
  • Isolated preadipocytes can be grown, expanded and differentiated into adipocytes in vitro, using methods and procedures such are described by Hauner et al. (Journal Clin. Invest., 34:1663-1670, 1989), Digby et al. (Diabetes 5:138-141, 1998), and International Application No. PCT/US00/022O8.
  • the differentiated adipocytes can be harvested from the culture medium using harvesting methods such as described by Freshney (Culture of Animal Cells pp. 310-312, 3 Ed., 1994) and implanted onto the wound preferably via a grafting chamber such as described in International Application No. PCT/US97/0061.
  • the grafting chamber can be removed from the wound after at least 1 day, preferably after at least 1 week subsequent to the implantation of the adipocytes.
  • the implanted adipocytes are exposed to an adipocyte modulator, such as, without limitation, a PPAR- ⁇ antagonist, preferably GW9662.
  • preadipocytes are implanted into the wound, so as to induce or accelerate the healing process of the skin wound.
  • the preadipocytes can be isolated, grown and expanded in vitro, using the methods and procedures such as described for adipocytes hereinabove, but omitting the differentiation step.
  • the non-differentiated preadipocytes are harvested from the culture medium and implanted onto the wound using procedures such as described for adipocytes hereinabove.
  • the implanted preadipocytes are exposed to an adipocyte modulator, such as, without limitation, a PPAR- ⁇ antagonist, preferably GW9662.
  • Adipocytes and/or preadipocytes can also be generated from cultured stem cells.
  • stem cells refers to embryonic or adult cells which are not terminally differentiated, which can divide without limit, and divides to yield cells that are either stem cells or which irreversibly differentiate to yield a new type of cell such as a preadipocytes or an adipocyte. Isolation and ex vivo expansion of stem cells can be performed using methods well known in the art. For example, Van Epps et al. (Blood Cells 20:411, 1994) and Emerson S. G. (Blood 87:3082, 1996) describe procedures for isolation and human hematopoietic stem cells from bone marrow, peripheral blood or a neonatal umbilical cord blood, and their expansion in culture.
  • Human embryonic stem cells can be prepared from human blastocyst cells, obtained from human in vivo preimplantation embryos, or in vitro fertilized embryos, using methods such as described in U.S. Pat. No. 5,843,780, and by Reubinoff et al. (Nature Biotech. 18:399, 2000).
  • Human mesenchymal stem cells hMSC
  • hMSC Human mesenchymal stem cells
  • the hMSC are found in bone marrow, blood, dermis and periosteum which are capable of differentiating into any of the specific types of mesenchymal tissues, such as an adipose tissue.
  • Stem cells can be a ⁇ ninistered directly onto the skin wound and allowed for differentiation into adipocytes in vivo with or without the co-administration of factors facilitating such differentiation.
  • the stem cells can be differentiated into preadipocytes or adipocytes ex vivo and then implanted onto the wound.
  • Cultured hMSC can be induced for adipogenic differentiation, using methods such as described in U.S Pat. No. 6,322,784.
  • adipocytes can be generated from primary hMSC by exposing the cells to a glucocorticoid and a compound capable of upregulating cAMP production, or by inhibiting degradation of cAMP, such as a phosphodiesterase inhibitor.
  • the adipocytes generated from stem cells are subsequently harvested and implanted onto wounds using procedures such as described above, so as to induce or accelerate the healing process of the skin wound.
  • wound cells are transformed to express and secrete an adipokine thereby inducing or accelerating the healing process of the skin wound.
  • the wound cells may be of any cell type which is involved in the wound healing process, such as keratinocytes, adipocytes or preadipocytes.
  • the cells can be transformed by a polynucleotide encoding an adipokine such as adipsin, adiponectin, resistin, leptin, lipo protein lipase, angiotensinogen, angiotesin-like 4, 1- Butyrylglycerol, matrix metalloproteinase 2, matrix metalloproteinase 9, and tumour neorosis factor ⁇ .
  • the cells can be transformed by a polynucleotide encoding a polypeptide capable of an adipokine activity, such as the polynucleotide encoding adipsin/complement D activity which is described in U.S. Patent 5,223,425.
  • the suitable polynucleotide can be introduced into cells by any one of a variety of known methods within the art. Such methods can be found generally described in Sambrook et al., [Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992)]; Ausubel et al., [Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Maryland (1989)]; Chang et al., [Somatic Gene Therapy, CRC Press, Ann Arbor, MI (1995)]; Vega et ah, [Gene Targeting, CRC Press, Ann Arbor MI (1995)]; Vectors [A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston MA (1988)] and Gilboa et al.
  • a preferred approach for introducing a polynucleotide encoding an adipokine into wound cells is by using a viral vector.
  • Viral vectors offer several advantages including higher efficiency of transformation, and targeting to, and propagation in, specific cell types. Viral vectors can also be modified with specific receptors or ligands to alter target specificity through specific cell receptors, such as cancer cell receptors.
  • Retro viral vectors represent one class of vectors suitable for use with the present invention. Defective retroviruses are routinely used in transfer of genes into mammalian cells [for review see Miller, A.D., Blood 76: 271 (1990)].
  • a recombinant retrovirus including an adipokine encoding polynucleotide can be constructed using well known molecular techniques.
  • Portions of the refroviral genome can be removed to render the retrovirus replication defective and the replication defective retrovirus can then packaged into virions, which can be used to infect target cells through the use of a helper virus and while employing standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in, for example, Ausubul et al., [eds, Current Protocols in Molecular Biology, Greene Publishing Associates, (1989)]. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells endothelial cells, lymphocytes, myoblasts, hepatocytes and bone marrow cells.
  • Another suitable expression vector may be an adenovirus vector.
  • the adenovirus is an extensively studied and routinely used gene transfer vector. Key advantages of an adenovirus vector include relatively high transduction efficiency of dividing and quiescent cells, natural tropism to a wide range of epithelial tissues and easy production of high titers [Russel, W.C. [J. Gen. Virol. 81: 57-63 (2000)].
  • the adenovirus DNA is transported to the nucleus, but does not integrate thereinto. Thus the risk of mutagenesis with adeno viral vectors is minimized, while short term expression is particularly suitable for treating cancer cells, such as multidrug resistant cancer cells.
  • Adenoviral vectors used in experimental cancer treatments are described by Seth et al. [Adenoviral vectors for cancer gene therapy. In: P. Seth (ed.) Adenoviruses: Basic biology to Gene Therapy, Austin, TX , (1999) pp. 103-
  • the viral vector may also include a nucleotide sequence encoding a signal for secretion of the antibody fragment to the outside of the cell.
  • Secretion signals generally contain a short sequence (7-20 residues) of hydrophobic amino acids. Secretion signals suitable for use in this invention are widely available and are well known in the art, see, for example by von Heijne [J. Mol. Biol. 184:99- 105 (1985)] and by Lej et al, [J. Bacteriol. 169: 4379 (1987)].
  • the recombinant vector can be administered in several ways. If viral vectors are used the procedure can take advantage of their target specificity and consequently, such vectors do not have to be administered locally at the tumor site. However, local adminisfration can provide a quicker and more effective freatment. Adminisfration of viral vectors can also be performed by, for example, infravenous or subcutaneous injection into the subject. Following injection, the viral vectors will circulate until they recognize host cells with appropriate target specificity for infection.
  • an adipokine or an adipocytes modulator can be used in therapy per se or as an active ingredient of a pharmaceutical composition.
  • composition refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
  • pharmaceutically acceptable carrier refers to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of an administered active ingredient.
  • An adjuvant is included under these phrases.
  • excipient refers to an inert substance added to a pharmaceutical composition to further facilitate adminisfration of an active ingredient.
  • excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
  • compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping and/or lyophilizing processes.
  • compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which can be used pharmaceutically.
  • the pharmaceutically acceptable carrier is suitable for topical application and can be, for example, but is not limited to, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment, as is further detailed hereinunder. Solid supports can also be used for prolonged release of the active ingredient into the wound.
  • Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose.
  • a therapeutically effective amount means an amount of active ingredients effective to induce or accelerate wound healing. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein, the assay disclosed herein and the Examples section that follows.
  • the therapeutically effective amount or dose can be estimated initially from a skin wound assay using experimental animals as described hereinabove. Such information can be used to more accurately determine useful doses in humans. Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of adminisfration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.l).
  • Dosage amount and interval may be adjusted individually to levels of the active ingredient which are sufficient to, for example, induce wound healing (minimal effective concentration, MEC).
  • MEC minimum effective concentration
  • the MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration.
  • dosing can be of a single or a plurality of administrations, with course of freatment lasting from several days to several weeks or until diminution of wound is achieved.
  • compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredients.
  • the pack may, for example, comprise metal or plastic foil formed into a tube for dispensing formulations for topical adminisfration.
  • the pack or dispenser device may be accompanied by instructions for adminisfration.
  • the pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration.
  • a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration.
  • Such notice for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
  • Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for freatment of an indicated condition, as if further detailed above.
  • the preferred mode of adminisfration of the active ingredients of the present invention is topical - local administration, yet systemic administration, via acceptable adminisfration routes, such as oral, intramuscular, infravenous, subcutaneous, transdermal, peritoneal, and the like using suitable formulations, as is well known in the art are not excluded.
  • the present invention provides novel methods and compositions for use in treatment of wounds by utilizing adipocytes, cells which can differentiate into adipocytes, adipocyte modulators and molecules secreted by adipocytes, for inducing or accelerating healing of wounds safely and effectively.
  • eosin was purchased from ICN Biomedicals Inc. (Aurora Ohaio USA) and entellan was purchased from MERCK (Darmstadt Germany).
  • Keratinocytes Primary keratinocytes were isolated from newborn skin as described in reference 18. Keratinocytes were cultured in Eagle's Minimal Essential Medium (EMEM) containing 8 % Chelex (Chelex-100, BioRad) freated fetal bovine serum. To maintain a proliferative basal cell phenotype, the final Ca 2+ concentration was adjusted to 0.05 mM. Experiments were performed five to seven days after plating. Keratinocytes migration assay: Primary mouse keratinocytes were untreated or freated with, PPAR ⁇ antagonist GW9662 ( ⁇ M) or PPAR ⁇ agonist froglitazone ( ⁇ M). Wound Scratch Assay was performed 24 hours following freatment, and representative fields were photographed immediately after the wounding (Day 0) and 48 hours later (Day 2). The average of wound closure represented as percentage in comparison to the initial width of the wound scratch (% of wound closure).
  • Wound healing assay Wounds were effected on backs of C57BL mice by 20 mm incision and were treated daily, for 6 days, with various agents. The mice were sacrificed six days after wounding. Wound biopsies were sampled, processed and analyzed morphologically and/or histochemically for various wound healing parameters, i.e., wound confraction, adipocytes migration and differentiation, epidermal migration, and epidermal closure.
  • Wound contraction analysis The wound area was measured before and after freatment and the percent reduction of the wound area was calculated.
  • H&E staining Parafin embedded wound-section slides were incubated at 60 °C for 60 minutes and were the de-parafinated by washing the slides twice with toluene (100%) for 10 minutes, once with ethanol 100 % for 15 minutes and once with ethanol 100 % for 10 minutes. . The de-parafinated slides were stained with hematoxylin (ready to use solution) for 10 minutes, rinsed with water, stained with eosin (0.5% in DDW) for 5 minutes, then washed with 70 % ethanol for 1 minute.
  • the slides were dehydrated by washing once with 95 % ethanol for 5 minutes, twice with 100 % ethanol for 5 minutes, and twice with xylene (100%) for 10 minutes, then sealed using entellan (MERCK Darmstadt Germany).
  • Keratin 4 and Keratin 14 staining Parafin embedded wound-section slides were de-parafinated as described for H&E staining above and incubated in blocking solution (5 % BSA and 5 % Tween 20TM in PBS) for 1 hour. The slides were then incubated with either anti-keratin 1, or with anti-keratin 14 antibody (Babco-Covance) in (1:1000) blocking solution (5 % BSA and 5 % Tween 20TM in PBS) at 4 °C overnight.
  • blocking solution 5 % BSA and 5 % Tween 20TM in PBS
  • the slides were washed five times with washing buffer (5 % Tween 20TM in PBS) followed by incubation with biotinilated goat anti-rabbit antibody (ZYMED Laboratories Inc.) suspended (1:200) in blocking solution (5 % BSA and 5 % Tween 20TM in PBS) for 1 hour.
  • the slides were then washed three times with washing buffer followed by incubation with a secondary biotinilated sfreptavidin antibody in blocking solution (1 : 300) for 1 hour at room temperature.
  • Migrating epidermal cells (keratinocytes) and recruited adipocytes were observed in seven day old wound tissue ( Figures 2A-B).
  • the observed recruited adipocytes appeared essentially free of stored fat (i.e., early adipocytes).
  • migrating keratinocytes were observed across the entire wound gap in about 60 % of the untreated wounds, while recruited adipocytes were also present in about 60 % of the untreated wounds.
  • Figure 1 also shows that migrating keratinocytes and recruited adipocytes were observed in about 90 % and 80 % of insulin-treated wounds, respectively.
  • adipsin complementing Factor D, which is secreted from adipocytes
  • incision wounds were effected on the back of C57BL mice and were freated daily, for 6 days, with PBS buffer (confrol), or with 1 ⁇ M adipsin.
  • the mice were sacrificed six days after wounding and the wounds were then analyzed.
  • adipsin substantially promoted wound confraction ( Figures 4, 5 and 7).
  • adipsin increased epidermal closure from about 15 % to about 30 %, and increased keratinocytes migration from about 30 % to about 65 %, as compared with the buffer confrol ( Figure 6).
  • adipokine such as adipsin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method and a pharmaceutical composition for inducing or accelerating a healing process of a skin wound are described. The method includes administering to the skin wound a therapeutically effective amount of an adipokine, an adipocyte modulator, an adipocyte, a cell capable of differentiating into an adipocyte, or a cell capable of secreting an adipokine, thereby inducing or accelerating the healing process of the skin wound.

Description

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR
ACCELERATING WOUND HEALING
FIELD AND BACKGROUND OF THE INVENTION
The present invention relates to methods and pharmaceutical compositions for accelerating the healing process of wounds. In particular the present invention utilizes bioactive molecules which are secreted by adipocytes (adipokines), and bioactive molecules which regulate adipocytes differentiation, proliferation and/or activity, for inducing or accelerating the healing process of skin wounds.
The primary goal in the treatment of wounds is to achieve wound closure. Open cutaneous wounds represent one major category of wounds and include burn wounds, neuropathic ulcers, pressure sores, venous stasis ulcers, and diabetic ulcers.
Open cutaneous wounds routinely heal by a process which comprises six major components: (i) inflammation; (ii) fibroblast proliferation; (iii) blood vessel proliferation; (iv) connective tissue synthesis; (v) epithelialization; and (vi) wound contraction. Wound healing is impaired when these components, either individually or as a whole, do not function properly. Numerous factors can affect wound healing, including malnutrition, infection, pharmacological agents (e.g., actinomycin and steroids), advanced age and diabetes [see Hunt and Goodson in Current Surgical Diagnosis & Treatment (Way; Appleton & Lange), pp. 86-98 (1988)]. There is also a common problem of wound healing following surgical procedures in various parts of the body, the surgery succeeds but the opening wound fails to heal.
Skin is a stratified squamous epithelium in which cells undergoing growth and differentiation are strictly compartmentalized. In the physiologic state, proliferation is confined to the basal cells that adhere to the basement membrane. Differentiation is a spatial process where basal cells lose their adhesion to the basement membrane, cease DNA synthesis and undergo a series of morphological and biochemical changes. The ultimate maturation step is the production of the cornified layer forming the protective barrier of the skin (1, 2). The earliest changes observed when basal cells commit to differentiate is associated with the ability of the basal cells to detach and migrate away from the basement membrane (3). Similar changes are associated with the wound healing process where cells both migrate into the wound area and proliferative capacity is enhanced. These processes are mandatory for the restructuring of the skin layers and induction of proper differentiation of the epidermal layers.
The analysis of mechanisms regulating growth, differentiation and migration of epidermal cells has been greatly facilitated by the development of culture systems for mouse and human keratinocytes (2, 4). In vitro, keratinocytes can be maintained as basal proliferating cells with a high growth rate. Furthermore, differentiation can be induced in vitro following the maturation pattern in the epidermis in vivo. The early events include loss of hemidesmosome components (3, 5) and a selective loss of the α6β4 integrin and cell attachment to matrix proteins. This suggests that changes in integrin expression are early events in keratinocyte differentiation. The early loss of hemidesmosomal contact leads to suprabasal migration of keratinocytes and is linked to induction of Keratin 1 (Kl) in cultured keratinocytes and in skin (1, 3, 6). Further differentiation to the granular layer phenotype is associated with down regulation of both βl and β4 integrin expression, loss of adhesion potential to all matrix proteins and is followed by cornified envelope formation and cell death. Differentiating cells ultimately sloughs from the culture dish as mature squames (2, 7). This program of differentiation in vitro closely follows the maturation pattern of epidermis in vivo.
Wound healing may be induced in vivo by various bioactive agents which directly or indirectly promote growth, differentiation and/or migration of epidermal cells. Thus, U.S. Pat. Nos. 5,591,709 and 5,461,030 describe the use of non-steroidal anabolic hormone such as insulin, growth hormone, triiodothyronine and thyroxine for inducing wound closure. U.S. Pat. No. 5,145,679 describes the use of insulin and pancreatin for inducing wound closure. U.S. Pat. No. 6,541,447 describes the use of a mixture of growth factors and growth hormones for inducing wound closure, and International Application No. PCT/ILO 1/00675 describes the use of PKC modulating agents for inducing wound closure. However, there is no teaching in the prior art for utilizing adipocytes, adipocyte modulators, or molecules secreted by adipocytes, for inducing or accelerating the processes associated with wound healing. There is thus a widely recognized need for, and it would be highly advantageous to have, new approaches for promoting wound healing. The present invention provides a novel approach for treating wounds by utilizing adipocytes, cells capable of differentiating into adipocytes, products secreted by adipocytes and adipocyte modulators, for inducing or accelerating the processes associated with wound healing.
SUMMARY OF THE INVENTION
While conducting experiments in wound healing research, the inventors of the present invention uncovered that adipocytes are closely associated with migrating keratinocytes at the wound gap during an early stage of the healing process, indicating that adipocytes, adipocyte modulators and adipokines are involved in, and hence may be used to influence, the wound healing process.
While reducing the present invention to practice, as is further delineated in the preferred embodiments and examples sections that follow, it was found that indeed administering to wounds an adipokine, or an adipocyte modulator, substantially and effectively promoted wound healing. Hence, according to one aspect of the present invention, there is provided a method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an adipokine, thereby inducing or accelerating the healing process of the skin wound.
According to another aspect of the present invention, there is provided a method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an agent capable of modulating expression and/or secretion of an adipokine, thereby inducing or accelerating the healing process of the skin wound.
According to yet another aspect of the present invention there is provided a method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an agent capable of modulating differentiation of adipocytes, thereby inducing or accelerating the healing process of the skin wound.
According to still another aspect of the present invention there is provided a method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an agent capable of attracting adipocytes to the skin wound, thereby inducing or accelerating the healing process of the skin wound.
According to an additional aspect of the present invention there is provided a method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an agent capable of enhancing proliferation of adipocytes in the skin wound, thereby inducing or accelerating the healing process of the skin wound.
According to yet an additional aspect of the present invention there is provided a method of inducing or accelerating a healing process of a skin wound, comprising implanting into the skin wound a therapeutically effective amount of adipocytes, so as to induce or accelerate the healing process of the skin wound.
According to still an additional aspect of the present invention there is provided a method of inducing or accelerating a healing process of a skin wound, comprising implanting into the skin wound a therapeutically effective amount of preadipocytes, thereby inducing or accelerating the healing process of the skin wound.
According to yet an additional aspect of the present invention there is provided a method of inducing or accelerating a healing process of a skin wound, comprising implanting into the skin wound a therapeutically effective amount of stem cells, thereby inducing or accelerating the healing process of the skin wound. According to a further aspect of the present invention there is provided a method of inducing or accelerating a healing process of a skin wound, comprising fransforming cells of the skin wound to express and secrete an adipokine, thereby inducing or accelerating the healing process of the skin wound.
According to yet a further aspect of the present invention there is provided a pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an adipokine, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
According to still a further aspect of the present invention there is provided a pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an agent capable of modulating expression and/or secretion of an adipokine, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
According to yet a further aspect of the present invention there is provided a pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an agent capable of modulating differentiation of adipocytes, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
According to still a further aspect of the present invention there is provided a pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an agent capable of attracting adipocytes to the skin- wound, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition. According to yet a further aspect of the present invention there is provided a pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an agent capable of enhancing proliferation of adipocytes, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
According to still a further aspect of the present invention there is provided a method of determining a capacity of an adipokine or an adipocyte modulator to induce or accelerate a healing process of a wound, comprising administering the adipokine or the adipocyte modulator to the wound, and evaluating the wound for a keratinocytes migration and/or an epidermal closure, to thereby determine the capacity of the adipokine or the adipocyte modulator to induce or accelerate healing of wounds.
According to further features in preferred embodiments of the invention described below, the adipokine is selected from the group consisting of adipsin, adiponectin, resistin, leptin, lipoprotein lipase, angiotensinogen, angiotesin-like 4, 1- Butyrylglycerol, matrix metalloproteinase 2, matrix metalloproteinase 9, vascular endothelial growth factor, interleukin 6, and tumor necrosis factor α. Preferably, the adipokine is adipsin, According to still further features in the described preferred embodiments the adipocytes modulating agent is a PPAR regulator, preferably a PPAR-γ antagonist, more preferably GW9662.
According to still further features in the described preferred embodiments the adipocytes are human adipocytes. Preferably, autologous human adipocytes.
According to still further features in the described preferred embodiments the preadipocytes are human preadipocytes. Preferably, autologous human preadipocytes.
According to still further features in the described preferred embodiments the stem cells are human stem cells. Preferably, autologous human stem cells. According to still further features in the described preferred embodiments the implanting further includes modulating expression and/or secretion of an adipokine.
According to still further features in the described preferred embodiments modulating is effected by differentiation.
According to still further features in the described preferred embodiments differentiation is effected by exposing the preadipocytes to a substance capable of enhancing differentiation of the preadipocytes into adipocytes.
According to still further features in the described preferred embodiments promoting differentiation is effected by exposing the stem cells to a substance capable of enhancing differentiation of the stem cells into adipocytes. According to still further features in the described preferred embodiments the wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
According to still further features in the described preferred embodiments the pharmaceutical composition carrier is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
According to still further features in the described preferred embodiments the pharmaceutical composition includes a solid support.
According to still further features in the described preferred embodiments the adipocytes modulator is an adipocyte differentiation modulator or an adipocyte activity modulator. i
7 According to still further features in the described preferred the wound is an incision wound which is effected in an experimental animal.
According to still further features in the described preferred embodiments the administrating of an adipokine or an adipocyte modulator is effected in one or more concentrations.
According to still further features in the described preferred embodiments the administrating of an adipokine or an adipocyte modulator is effected in one or more applications.
The present invention provides novel pharmaceutical compositions and methods for treating wounds utilizing adipocytes, cells capable of differentiating into adipocytes, adipocytes modulators and molecules secreted by adipocytes, for inducing or accelerating wound healing.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice. In the drawings:
FIG. 1 illustrates the effect of insulin on adipocytes recruitment and epidermal cells migration at the wound area. Wounds were effected on the back of C57BL mice by incision. The wounds were treated daily with topical application of healing- inducing insulin (1 μM) for six days, then the mice were sacrificed and their wounds analyzed for epidermal cells migration and adipocytes recruitment. Epidermal cell migration was determined by K14 antibody staining and was considered positive if the wound was stained positive across the entire wound gap. Adipocytes recruitment was determined by H&E staining and was considered positive if adipocytes were detected inside the granulation tissue. The dark bars represent the insulin treatment and the light bars represent the buffer-treated control. The results are presented as percent of closed (positive) wounds and each bar represents the mean of six replications ± standard error.
FIGs. 2A-B are histochemical micrographs illustrating the association of adipocytes with the wound healing process. Wounds were effected on the back of C57BL mice by incision. The mice were sacrificed seven days after wounding, then sectioned and stained with K14 antibody to highlight migrating epidermal cells. The micrographs show that recruited adipocytes are present at the wound gap in abundance during an early stage of the wound healing process (Figure 2A, x20 magnification; Figure 2B, xlO magnification).
FIG. 3 illustrates the effect of a PPARγ antagonist (GW9662) on primary keratinocytes migration in vitro. Cultured keratinocytes were either untreated (control), or treated with 2 μM GW9662. The keratinocytes migration was observed under a light microscope. The upper panels show micrographs of pre-treated (Day 0) cultures, and the bottom left and panels show the resulting control and treated cultures, respectively (Day 2). The blue lines mark the edges of migrating keratinocytes and the arrows point out the enhanced migration of GW9662 treated cultures, as compared with the untreated control.
FIG. 4 is a graph illustrating the effects of a PPARγ antagonist (GW9662) and adipsin on wound healing in vivo. Wounds were effected on the back of C57BL mice by incision and the wounds were then measured (Day 0). The wounds areas treated daily with topical application of PBS (control), adipsin, or GW9662 2 μM for six days. Mice were then sacrificed and their wound areas were measured (Day 6). The portion of the wound area contracted in the six days from the initial wound area was calculated (% wound contraction) for each treatment. The graph shows that both
GW9662 and adipsin promoted a substantial wound contraction, as compared with the buffer-treated control.
FIG. 5 is a histochemical micrograph illustrating the effects of a PPARγ antagonist (GW9662) and adipsin on wound closure in vivo. Wounds were effected on the back of C57BL mice by incision and their area were then measured (Day 0). The wounds were treated daily, for six days, with topical application of PBS (control), adipsin 1 μM, or GW9662 2 μM. The mice were then sacrificed, their wounds were fixed with paraformaldehyde and observed under a binocular microscope at x5 magnification. The micrograph shows that the areas of wounds which were treated with GW9662, or with adipsin, are substantially smaller than the wound area of the buffer control. FIG. 6 illustrates the effect of adipsin on epidermal cell migration and wound closure. Wounds were effected on the back of C57BL mice by incision. The wounds were treated daily with topical application of 1 μM adipsin for seven days, then sacrificed, sectioned and analyzed for epidermal closure and migration by K14 antibody staining. Epidermal closure was considered positive if the wound was stained positive through the entire wound gap. Epidermal migrating was considered positive if the wound was stained positive but not entirely across the wound gap. The bar graph shows that both epidermal closure and epidermal migration were markedly enhanced by adipsin. Each bar represents the mean of six replications.
FIG. 7 is a histochemical micrograph illustrating the effects of a PPARγ antagonist (GW9662) and adipsin on wound closure (contraction). Wounds were effected on the back of C57BL mice by incision and were treated daily, for 6 days, with adipsin (lμM), GW9662 (2μM), or untreated (control). The treated mice were sacrificed six days after wounding. Histochemical wound sections were performed, stained with H&E (upper panel) or with K14 antibody (lower panel), and observed under a light microscope at x5 magnification. The contraction was considered positive if both dermal wound sides (marked by black lines) could be observed in a single field. The opened wound area in the untreated control section (right) was too large to be contained in a single field (thus considered a negative dermal contraction), while the adipsin treated section (left) and the GW9662 treated section (center) show positive dermal contractions.
FIG. 8 illustrates the effect of a PPARγ agonist (froglitazone) on primary keratinocytes migration in vitro. Cultured keratinocytes were either untreated (confrol), or treated with 100 μM froglitazone, and their migration was observed under a light microscope. The upper panels (Time 0) show micrographs of pre-treated cultures, and the bottom left and right panels show the resulting confrol and treated cultures, respectively (within 48 hours). The lines mark the edges of cultured keratinocytes and indicate a substantially inhibited migration of cultured keratinocytes treated with froglitazone, as compared with the untreated control.
FIG. 9 is a histochemical micrograph illustrating the effects of insulin and a PPARγ agonist (froglitazone) on wound closure in vivo. Wounds were effected on the back of C57BL mice by incision and were treated daily, for 6 days, with topical application of PBS (confrol), insulin (10 nM), froglitazone (100 μM), or froglitazone (100 μM) + insulin (10 nM) combined. The mice were then sacrificed, their wounds were fixed with paraformaldehyde and observed under a binocular microscope at x5 magnification. The micrograph shows that the insulin-treated wound area is substantially smaller than the buffer confrol, while the froglitazone and the froglitazone + insulin treated wounds are substantially larger than the buffer confrol.
FIG. 10 illustrates the effect of insulin and a PPARγ agonist (froglitazone) on wound closure incidence. Wounds were effected on the back of C57BL mice by incision. The wounds were treated daily with topical application of PBS (confrol), insulin (10 nM), troglitazone (100 μM), or troglitazone (100 μM) + insulin (10 nM) for six days, then sacrificed, sectioned and analyzed for wound closure. The wound closure was determined by K14 and Kl antibody staining. Wound closure was considered positive if the wound was stained positive throughout the entire wound gap. Each bar represents the mean of six replications.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is of methods and pharmaceutical compositions for accelerating the healing process of wounds. Specifically, the present invention utilizes adipocytes, cells capable of differentiating into adipocytes, bioactive molecules secreted by adipocytes (adipokines) and adipocyte modulators, for accelerating the healing process of skin wounds.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the examples section. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
Adult skin includes two layers, a keratinized stratified epidermis and an underlying thick layer of collagen-rich dermal connective tissue providing support and nourishment. Slrin serves as the protective barrier against the outside world. Therefore, any injury or break in the skin must be rapidly and efficiently mended. As described in the Background section hereinabove, the first stage of skin repair is achieved by formation of the clot that plugs the initial wound. Thereafter, inflammatory cells, fibroblasts and capillaries invade the clot to form a granulation tissue. The following stages involve re-epithelization of the wound, where basal keratinocytes have to lose their hemidesmosomal contacts and migrate into the granulation tissue to cover the wound. Following keratinocyte migration, keratinocytes enter a proliferative boost, which allows replacement of cells lost during wound formation. After the wound is covered by a monolayer of keratinocytes (i.e., epidermal closure) new stratified epidermis is formed and the new basement membrane is reestablished (8-11). While conducting experiments in wound healing research, the inventors unexpectedly uncovered that adipocytes are closely associated with migrating keratinocytes at the wound area, during an early stage of the wound healing process. Accordingly, Example 1 of the Examples section that follows illustrates that the appearance of migrating keratinocytes at the wound gap was directly correlated with appearance of recruited adipocytes at the same area. Furthermore, insulin freated wounds recruited more adipocytes to the wound gap, and subsequently healed faster, than confrol, untreated wounds. This newly uncovered close association of adipocytes and migrating keratinocytes at healing wounds, coupled with the direct correlation observed between recruited adipocytes incidence and wound healing efficiency, indicate that adipocytes, adipocyte modulators and adipocyte products (adipokines) are involved in, and hence maybe used to influence, the wound healing process. Adipocytes secrete a number of bioactive molecules, known as adipokines, which play a role in the maintenance of energy homeostasis by regulating insulin secretion, insulin action, glucose and lipid metabolism, energy balance, inflammation, and reproduction.
However, the possible involvement of adipocytes-secreted bioactive molecules in wound healing has not been taught nor suggested by the prior art.
Based on the initial findings described above, and while further reducing the present invention to practice, the inventors of the present invention anticipated and thereafter uncovered that an exemplary adipokine, adipsin, which was chosen out of the list of known adipokones, substantially accelerated keratinocytes migration in vitro and effectively promoted healing of skin wounds in vivo (see in Example 3 of the Examples section which follows).
Thus, according to one aspect of the present invention there is provided a method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an adipokine, thereby inducing or accelerating the healing process of the skin wound.
The term "wound" as used herein refers broadly to injuries to the skin and subcutaneous tissue initiated in any one of a variety of ways (e.g., pressure sores from extended bed rest, wounds induced by trauma, cuts, ulcers, burns, surgical incisions and the like) and with varying characteristics. Wounds are typically classified into one of four grades depending on the depth of the wound: (i) Grade I: wounds limited to the epithelium; (ii) Grade II: wounds extending into the dermis; (iii) Grade HI: wounds extending into the subcutaneous tissue; and (iv) Grade IV (or full-thickness wounds): wounds wherein bones are exposed (e.g., a bony pressure point such as the greater frochanter or the sacrum). The term "partial thickness wound" used herein refers to wounds that encompass Grades I-HI; examples of partial thickness wounds include burn wounds, pressure sores, venous stasis ulcers, and diabetic ulcers. The term "deep wound" used herein is meant to include both Grade HI and
Grade IV wounds.
The term "chronic wound" used herein refers to a wound that has not healed within thirty days. The term "healing" in respect to a wound refers to a process to repair a wound as by scar formation.
The present invention contemplates treating all wound types, including deep wounds and chronic wounds.
The term "adipokine" as used herein refers to any bioactive molecule which is secreted by adipocytes in vivo or in vitro, including, but not limited to, adipocyte- secreted enzymes, growth factors, cytokines and hormones. Preferably, the adipokine of the present invention is selected from the group consisting of complement factors D
(adipsin), C3 and B; vascular endothelial growth factor (VGEF), Adiponectin
(Acrp30); resistin; leptin; lipoprotein lipase (LPL); angiotensinogen; angiotesin like 4; 1 -Butyrylglycerol (monobutyrin); matrix metalloproteinases 2 and 9; tumour neorosis factor α (TNFo;), and interleukin 6. Preferably the adipokine is adipsin.
In addition to administering adipokines to wounds, the healing of wounds may be induced or accelerated according to certain embodiments of the present invention by an adipocytes modulator. The phrase "adipocytes modulator" as used herein refers to any molecule capable of modulating expression and/or secretion of adipokines from adipocytes, adipocytes differentiation, adipocytes proliferation, adipocytes migration or attracting adipocytes to the wound gap.
Adipocytes are differentiated from preadipocytes in a process known as adipogenesis. In culture, adipogenesis is fully dependent on insulin, dexamethasone and isobuthylmethylxanthine, stressing the involvement of insulin, glucocorticoid and cAMP pathways.
While many signaling and biochemical pathways play an imperative role in this process, most of the known changes that occur during adipogenesis are at the gene franscription level. The key transcriptional factors involved in the adipogenic process include proteins belonging to the CCAAT/enhancer binding protein family, adipocyte determination and differentiation dependent factor 1 (also known as sterol regulatory element - binding protein 1), and peroxisome proliferators-activator receptor γ
(Rangwala and Lazar, Ann. Rev. Nutt. 20:535-539, 2000).
The peroxisome proliferator-activated receptors (PPARs) comprise three types,
PPARα, PPARβ and PPARγ. They are ligand-inducible nuclear receptors which directly modulate gene activity by binding to defined nucleotide sequences in the promoter region of target genes. PPARγ plays a crucial role in the terminal differentiation by transactivation of adipocyte-specific genes. Recent results suggest a cross talk between PPARs and the cholesterol metabolism pathway in the epidermis.
All PPAR isoforms are expressed in embryonic and mature skin. PPARγ expression dramatically increases at the late stages of fetal maturation. In postnatals, as well as in adult skin, the expression of PPARγ is decreased. An important role has been suggested for PPARβ and PPARα in keratinocyte differentiation during epidermis formation (Wabli W., Swiss Med. Wkly. 132: 83-91, 2002). It has been also demonstrated that PPARβ and PPARα are up-regulated at the edges of wounded skin and that null mice of these isoformes are wound healing impaired (Michalnik et al., J. Cell Biol. 154: 799-814, 2001). Yet, the involvement of PPARγin the wound healing process has not been described nor suggested in the prior art.
U.S. Pat. No. 6,403,656 describes the use PPARγ activators for treating skin disorders related to an anomaly of the differentiation of epidermic cells. In addition, International Application No. PCT/US99/28101 describes the use of PPARγ activators, such as a prostaglandin J2 or D2, for treating obesity and diabetes. However, none of these disclosures teaches or suggests using PPARγ activators, or inhibitors, for use in healing wounds.
While further reducing the present invention to practice, the inventors of the present invention uncovered that PPARγ activity is inversely related to the wound healing process. Accordingly, Example 2 of the Examples section which follows illustrates that administering troglitazone, a PPARγ agonist, inhibited wound confraction. On the other hand, administering GW9662, which is a PPARγ antagonist, promoted wound confraction. Thus, according to another aspect of the present invention there is provided a method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an agent capable of modulating differentiation of adipocytes, thereby inducing or accelerating the healing process of the skin wound. The agent according to this aspect of the present invention may be any agonist or antagonist of any factor, such as a transcriptional factor which is involved in adipocytes differentiation, including, but not limited to, a protein belonging to the CCAAT/enhancer binding protein family, adipocyte determination and differentiation dependent factor 1, and PPARγ. Preferably, the agent is a PPAR-γ antagonist, more preferably GW9662.
In addition to adipocytes differentiation modulators, the wound healing process may be promoted by utilizing other adipocyte modulators. Thus, according to the teaching of the present invention, a healing process of a skin wound can be induced or accelerated by adrninistering to the skin wound a therapeutically effective amount of an agent which is capable of: (i) modulating expression and/or secretion of an adipokine from adipocytes, (ii) enhancing adipocytes proliferation, (ii) enhancing adipocytes migration, or (iii) attracting adipocytes to the wound area. An assay readily exercisable by one ordinarily skilled in the relevant art of determining whether a specific agent, e.g., an adipokine or an adipocyte modulator, is offered in context of the present invention to test whether any such specific agent is indeed an inducer or accelerator of a wound healing process.
Thus, the capacity of an adipokine or an adipocytes modulator to induce or accelerate a healing process of a skin wound can be determined by administering the adipokine or the adipocytes modulator in question to a skin wound and evaluating the treated wounds for keratinocytes migration and/or epidermal closure.
Preferably, the skin wound is effected on the backs of a C57BL mouse by incision and freated with one or more applications, each with one or more concentrations of the adipokine.
A desired time period post wounding, preferably about 6 days, the mouse is sacrificed and wound biopsies are sampled. The wound biopsies are then analyzed for keratinocytes migration to the wound gap and/or for epidermal closure of the wound gap, using methods known in the art, preferably using the procedures as described in the Examples section that follows.
A significant increase in the incidence of keratinocytes migration and/or epidermal closure, over an untreated confrol, would determine that a tested adipokine or adipocytes modulator is capable of inducing or accelerating a healing process of a skin wound.
According to another aspect of the present invention, adipocytes, preferably autologous adipocytes, are implanted into the wound, so as to induce or accelerate the healing process of the skin wound.
Adipocytes may be obtained from an adipose tissue of any animal source, preferably from a human donor, most preferably from an autologous human source. The adipose tissue may be sampled from a subcutaneous or perirenal site, preferably subcutaneous, using well recognized protocols such as surgical, suction, liposuction, penniculectomy, or via biopsy. The adipocyte cells are preferably separated from the adipose tissue sample by using enzymes which destroy physical cell contacts (e.g., collagenases), or by using mechanical agitation, sonic or ultrasonic energy and the like. The separated adipocytes can be cultured using suitable tissue culture techniques known in the art such as, for example, described in details in International Application PCT/US00/30623. The cultured adipocytes are allowed to grow until near-confluence is reached, then removed by gentle scrapping from the growth medium and implanted onto the wound.
Adipocytes can also be generated from cultured preadipocytes. The term "preadipocyte" as used herein refers to any cell which is capable of differentiating into an adipocyte. Preferably, preadipocytes are human adipocytes, more preferably autologous adipocytes isolated from the patient's own adipose or other tissue. The adipose tissue may be sampled from subcutaneous or perirenal sites using well recognized protocols such as surgical, suction liposuction, penniculectomy, or via biopsy. The preadipocyte cells may be isolated from the sampled tissue by using methods such as described by Rodbell et al. (Meth. Enzymol. 31:103-114, 1974). Isolated preadipocytes can be grown, expanded and differentiated into adipocytes in vitro, using methods and procedures such are described by Hauner et al. (Journal Clin. Invest., 34:1663-1670, 1989), Digby et al. (Diabetes 5:138-141, 1998), and International Application No. PCT/US00/022O8. The differentiated adipocytes can be harvested from the culture medium using harvesting methods such as described by Freshney (Culture of Animal Cells pp. 310-312, 3 Ed., 1994) and implanted onto the wound preferably via a grafting chamber such as described in International Application No. PCT/US97/0061. The grafting chamber can be removed from the wound after at least 1 day, preferably after at least 1 week subsequent to the implantation of the adipocytes. Optionally, the implanted adipocytes are exposed to an adipocyte modulator, such as, without limitation, a PPAR-γ antagonist, preferably GW9662.
According to another aspect of the present invention, preadipocytes are implanted into the wound, so as to induce or accelerate the healing process of the skin wound. The preadipocytes can be isolated, grown and expanded in vitro, using the methods and procedures such as described for adipocytes hereinabove, but omitting the differentiation step. The non-differentiated preadipocytes are harvested from the culture medium and implanted onto the wound using procedures such as described for adipocytes hereinabove. Optionally, the implanted preadipocytes are exposed to an adipocyte modulator, such as, without limitation, a PPAR-γ antagonist, preferably GW9662. Adipocytes and/or preadipocytes can also be generated from cultured stem cells. The phrase "stem cells" as used herein refers to embryonic or adult cells which are not terminally differentiated, which can divide without limit, and divides to yield cells that are either stem cells or which irreversibly differentiate to yield a new type of cell such as a preadipocytes or an adipocyte. Isolation and ex vivo expansion of stem cells can be performed using methods well known in the art. For example, Van Epps et al. (Blood Cells 20:411, 1994) and Emerson S. G. (Blood 87:3082, 1996) describe procedures for isolation and human hematopoietic stem cells from bone marrow, peripheral blood or a neonatal umbilical cord blood, and their expansion in culture. Human embryonic stem cells (hESC), can be prepared from human blastocyst cells, obtained from human in vivo preimplantation embryos, or in vitro fertilized embryos, using methods such as described in U.S. Pat. No. 5,843,780, and by Reubinoff et al. (Nature Biotech. 18:399, 2000). Human mesenchymal stem cells (hMSC) can be isolated and expanded using methods such as described in U.S. Pat. Nos. 5,197985, 5,486,359 and 6,214,369. The hMSC are found in bone marrow, blood, dermis and periosteum which are capable of differentiating into any of the specific types of mesenchymal tissues, such as an adipose tissue. Stem cells can be aό^ninistered directly onto the skin wound and allowed for differentiation into adipocytes in vivo with or without the co-administration of factors facilitating such differentiation. Alternatively, the stem cells can be differentiated into preadipocytes or adipocytes ex vivo and then implanted onto the wound. Cultured hMSC can be induced for adipogenic differentiation, using methods such as described in U.S Pat. No. 6,322,784. Accordingly, adipocytes can be generated from primary hMSC by exposing the cells to a glucocorticoid and a compound capable of upregulating cAMP production, or by inhibiting degradation of cAMP, such as a phosphodiesterase inhibitor. The adipocytes generated from stem cells are subsequently harvested and implanted onto wounds using procedures such as described above, so as to induce or accelerate the healing process of the skin wound.
In an alternative embodiment of the present invention, wound cells are transformed to express and secrete an adipokine thereby inducing or accelerating the healing process of the skin wound. The wound cells may be of any cell type which is involved in the wound healing process, such as keratinocytes, adipocytes or preadipocytes. The cells can be transformed by a polynucleotide encoding an adipokine such as adipsin, adiponectin, resistin, leptin, lipo protein lipase, angiotensinogen, angiotesin-like 4, 1- Butyrylglycerol, matrix metalloproteinase 2, matrix metalloproteinase 9, and tumour neorosis factor α. Alternatively, the cells can be transformed by a polynucleotide encoding a polypeptide capable of an adipokine activity, such as the polynucleotide encoding adipsin/complement D activity which is described in U.S. Patent 5,223,425.
The suitable polynucleotide can be introduced into cells by any one of a variety of known methods within the art. Such methods can be found generally described in Sambrook et al., [Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992)]; Ausubel et al., [Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Maryland (1989)]; Chang et al., [Somatic Gene Therapy, CRC Press, Ann Arbor, MI (1995)]; Vega et ah, [Gene Targeting, CRC Press, Ann Arbor MI (1995)]; Vectors [A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston MA (1988)] and Gilboa et al. [Biotechniques 4 (6): 504-512 (1986)] and include, for example, stable or transient fransfection, lipofection, elecfroporation and infection with recombinant viral vectors. In addition, see United States patent 4,866,042 for vectors involving the central nervous system and also United States patents 5,464,764 and 5,487,992 for positive-negative selection methods for inducing homologous recombination.
A preferred approach for introducing a polynucleotide encoding an adipokine into wound cells is by using a viral vector. Viral vectors offer several advantages including higher efficiency of transformation, and targeting to, and propagation in, specific cell types. Viral vectors can also be modified with specific receptors or ligands to alter target specificity through specific cell receptors, such as cancer cell receptors. Retro viral vectors represent one class of vectors suitable for use with the present invention. Defective retroviruses are routinely used in transfer of genes into mammalian cells [for review see Miller, A.D., Blood 76: 271 (1990)]. A recombinant retrovirus including an adipokine encoding polynucleotide can be constructed using well known molecular techniques. Portions of the refroviral genome can be removed to render the retrovirus replication defective and the replication defective retrovirus can then packaged into virions, which can be used to infect target cells through the use of a helper virus and while employing standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in, for example, Ausubul et al., [eds, Current Protocols in Molecular Biology, Greene Publishing Associates, (1989)]. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells endothelial cells, lymphocytes, myoblasts, hepatocytes and bone marrow cells.
Another suitable expression vector may be an adenovirus vector. The adenovirus is an extensively studied and routinely used gene transfer vector. Key advantages of an adenovirus vector include relatively high transduction efficiency of dividing and quiescent cells, natural tropism to a wide range of epithelial tissues and easy production of high titers [Russel, W.C. [J. Gen. Virol. 81: 57-63 (2000)]. The adenovirus DNA is transported to the nucleus, but does not integrate thereinto. Thus the risk of mutagenesis with adeno viral vectors is minimized, while short term expression is particularly suitable for treating cancer cells, such as multidrug resistant cancer cells. Adenoviral vectors used in experimental cancer treatments are described by Seth et al. [Adenoviral vectors for cancer gene therapy. In: P. Seth (ed.) Adenoviruses: Basic biology to Gene Therapy, Landes, Austin, TX , (1999) pp. 103-
120].
Features that limit expression to particular cell types can also be included.
Such features include, for example, promoter and regulatory elements that are specific for the desired cell type. The viral vector may also include a nucleotide sequence encoding a signal for secretion of the antibody fragment to the outside of the cell.
Secretion signals generally contain a short sequence (7-20 residues) of hydrophobic amino acids. Secretion signals suitable for use in this invention are widely available and are well known in the art, see, for example by von Heijne [J. Mol. Biol. 184:99- 105 (1985)] and by Lej et al, [J. Bacteriol. 169: 4379 (1987)].
The recombinant vector can be administered in several ways. If viral vectors are used the procedure can take advantage of their target specificity and consequently, such vectors do not have to be administered locally at the tumor site. However, local adminisfration can provide a quicker and more effective freatment. Adminisfration of viral vectors can also be performed by, for example, infravenous or subcutaneous injection into the subject. Following injection, the viral vectors will circulate until they recognize host cells with appropriate target specificity for infection.
According to the present invention an adipokine or an adipocytes modulator can be used in therapy per se or as an active ingredient of a pharmaceutical composition.
As used herein the phrase "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
Hereinafter, the phrases "physiologically acceptable carrier" and
"pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of an administered active ingredient. An adjuvant is included under these phrases.
Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate adminisfration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
Techniques for formulation and adminisfration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.
Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping and/or lyophilizing processes.
Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which can be used pharmaceutically. According to the present invention, the pharmaceutically acceptable carrier is suitable for topical application and can be, for example, but is not limited to, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment, as is further detailed hereinunder. Solid supports can also be used for prolonged release of the active ingredient into the wound. Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to induce or accelerate wound healing. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein, the assay disclosed herein and the Examples section that follows.
For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from a skin wound assay using experimental animals as described hereinabove. Such information can be used to more accurately determine useful doses in humans. Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of adminisfration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.l).
Dosage amount and interval may be adjusted individually to levels of the active ingredient which are sufficient to, for example, induce wound healing (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration.
Depending on the severity and responsiveness of the wound to be freated, dosing can be of a single or a plurality of administrations, with course of freatment lasting from several days to several weeks or until diminution of wound is achieved.
The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of adminisfration, the judgment of the prescribing physician, etc. Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredients. The pack may, for example, comprise metal or plastic foil formed into a tube for dispensing formulations for topical adminisfration. The pack or dispenser device may be accompanied by instructions for adminisfration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for freatment of an indicated condition, as if further detailed above.
It will be appreciated that the preferred mode of adminisfration of the active ingredients of the present invention is topical - local administration, yet systemic administration, via acceptable adminisfration routes, such as oral, intramuscular, infravenous, subcutaneous, transdermal, peritoneal, and the like using suitable formulations, as is well known in the art are not excluded.
Thus, the present invention provides novel methods and compositions for use in treatment of wounds by utilizing adipocytes, cells which can differentiate into adipocytes, adipocyte modulators and molecules secreted by adipocytes, for inducing or accelerating healing of wounds safely and effectively.
Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
EXAMPLES Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.
Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A Laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-HI Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-HI
Cellis, J. E., ed. (1994); "Culture of Animal Cells -A Manual of Basic Technique" by
Freshney, Wiley-Liss, N. Y. (1994), Third Edition; "Current Protocols in
Immunology" Volumes I-HI Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Ha es, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization -A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.
MATERIALS AND EXPERIMENTAL METHODS
Materials: All standard chemicals were from (Sigma-Aldrich, St. Louis, USA). Paraplast Embedding Medium was also purchased from Sigma. Anti keratin 14 antibody and anti keratin 1 polyclonal antibody were purchase from Bacto-Covance (Richmond, CA USA). Biotinylated goat anti-rabbit antibody and sfreptavidin- horseradish peroxidase (HRP) were purchased from ZYMED Laboratories Inc. (San Francisco, CA USA). GW9662 was purchased from Cayman Chemicals (Ann Arbor Michigan USA). Adipsin (complementing factor D) was purchased from Calibiochem (San Diego CA USA). Hematoxylin was purchased from DAKO corp. (Carpinteria
CA USA) eosin was purchased from ICN Biomedicals Inc. (Aurora Ohaio USA) and entellan was purchased from MERCK (Darmstadt Germany).
Isolation and culture of murine keratinocytes: Primary keratinocytes were isolated from newborn skin as described in reference 18. Keratinocytes were cultured in Eagle's Minimal Essential Medium (EMEM) containing 8 % Chelex (Chelex-100, BioRad) freated fetal bovine serum. To maintain a proliferative basal cell phenotype, the final Ca2+ concentration was adjusted to 0.05 mM. Experiments were performed five to seven days after plating. Keratinocytes migration assay: Primary mouse keratinocytes were untreated or freated with, PPARγ antagonist GW9662 (μM) or PPARγ agonist froglitazone (μM). Wound Scratch Assay was performed 24 hours following freatment, and representative fields were photographed immediately after the wounding (Day 0) and 48 hours later (Day 2). The average of wound closure represented as percentage in comparison to the initial width of the wound scratch (% of wound closure).
Wound healing assay: Wounds were effected on backs of C57BL mice by 20 mm incision and were treated daily, for 6 days, with various agents. The mice were sacrificed six days after wounding. Wound biopsies were sampled, processed and analyzed morphologically and/or histochemically for various wound healing parameters, i.e., wound confraction, adipocytes migration and differentiation, epidermal migration, and epidermal closure.
Wound contraction analysis: The wound area was measured before and after freatment and the percent reduction of the wound area was calculated.
Preparation of paraffin embedded wound sections: Wound biopsies were fixed in 4 % paraformaldehyde then dehydrated in increasing concentrations of ethanol (50 - 100 %). The dehydrated preparations were immersed first in paraffin 50 % and xylene 50 % solution, then in pure paraffin. The paraffin blocks were then sectioned by a microtome and the sections were mounted on Super Frost+™ slides.
H&E staining: Parafin embedded wound-section slides were incubated at 60 °C for 60 minutes and were the de-parafinated by washing the slides twice with toluene (100%) for 10 minutes, once with ethanol 100 % for 15 minutes and once with ethanol 100 % for 10 minutes. . The de-parafinated slides were stained with hematoxylin (ready to use solution) for 10 minutes, rinsed with water, stained with eosin (0.5% in DDW) for 5 minutes, then washed with 70 % ethanol for 1 minute.
Thereafter, the slides were dehydrated by washing once with 95 % ethanol for 5 minutes, twice with 100 % ethanol for 5 minutes, and twice with xylene (100%) for 10 minutes, then sealed using entellan (MERCK Darmstadt Germany).
Keratin 4 and Keratin 14 staining: Parafin embedded wound-section slides were de-parafinated as described for H&E staining above and incubated in blocking solution (5 % BSA and 5 % Tween 20™ in PBS) for 1 hour. The slides were then incubated with either anti-keratin 1, or with anti-keratin 14 antibody (Babco-Covance) in (1:1000) blocking solution (5 % BSA and 5 % Tween 20™ in PBS) at 4 °C overnight. Thereafter, the slides were washed five times with washing buffer (5 % Tween 20™ in PBS) followed by incubation with biotinilated goat anti-rabbit antibody (ZYMED Laboratories Inc.) suspended (1:200) in blocking solution (5 % BSA and 5 % Tween 20™ in PBS) for 1 hour. The slides were then washed three times with washing buffer followed by incubation with a secondary biotinilated sfreptavidin antibody in blocking solution (1 : 300) for 1 hour at room temperature. Thereafter, the slides were washed twice with washing buffer for 5 minutes, once with PBS for 5 minutes and once with TRIS buffer (0.05 M in PBS), followed by incubation in DAB reagent (2 tablets 1 gold 1 silver dissolved in DDW) for color development. The reaction was terminated by immersing the slides in water followed by counterstaining with eosin (ICN, 0.5% in DDW).
EXPERIMENTAL RESULTS EXAMPLE 1 Association of adipocytes with migrating keratinocytes during the wound healing process
Migrating epidermal cells (keratinocytes) and recruited adipocytes were observed in seven day old wound tissue (Figures 2A-B). The observed recruited adipocytes appeared essentially free of stored fat (i.e., early adipocytes). As can be seen in Figure 1, migrating keratinocytes were observed across the entire wound gap in about 60 % of the untreated wounds, while recruited adipocytes were also present in about 60 % of the untreated wounds. Figure 1 also shows that migrating keratinocytes and recruited adipocytes were observed in about 90 % and 80 % of insulin-treated wounds, respectively.
These results reveal that migration of keratinocytes to the wound gap area is closely associated with recruitment of adipocytes to the same area during an early stage of the wound healing process. The results thus indicate that migrating adipocytes, which are not fully differentiated into fat accumulating cells, are involved in the wound healing process.
EXAMPLE 2 The effect of PPARy modulators on keratinocytes migration and wound contraction
The effect of inhibiting or enhancing the activity of peroxisome proliferators- activated receptor gamma (PPARγ) on keratinocytes migration was evaluated in vitro.
As can be seen in Figure 3, the freatment of cultured primary mouse keratinocytes with the PPARγ antagonist GW9662 promoted keratinocytes migration. On the other hand, the freatment of cultured keratinocytes with the PPARγ agonist froglitazone inhibited keratinocytes migration (Figure 8).
The effect of inhibiting or enhancing the activity of PPARγ using PPARγ antagonist and agonist, respectively, on wound healing was also evaluated in vivo. Accordingly, incision wounds were effected on the back of C57BL mice and were freated daily, for 6 days, with PBS buffer (confrol), or with various agents. The mice were sacrificed six days after wounding and the wounds were then analyzed. As can be seen in Figures 4, 5 and 6, the treatment with GW9662 (a PPARγ antagonist) promoted wound contraction, as compared with the confrol. On the other hand, a similar freatment with froglitazone (a PPARγ agonist) inhibited wound contraction
(Figure 9). Furthermore, froglitazone impaired insulin-induced wound healing
(Figures 9 and 10).
Hence, the results clearly demonstrate that PPARγ activity hinders the healing of wounds and that PPARγ inhibition can effectively promote the wound healing process. Accordingly, the results indicate that PPARγ antagonists, such as GW9662 can be used to effectively accelerate wound healing. EXAMPLE 3
The effect of adipsin on keratinocytes migration and wound contraction
The effect of adipsin (complementing Factor D, which is secreted from adipocytes) on wound healing was evaluated in vivo. Accordingly, incision wounds were effected on the back of C57BL mice and were freated daily, for 6 days, with PBS buffer (confrol), or with 1 μM adipsin. The mice were sacrificed six days after wounding and the wounds were then analyzed. As illustrated in Figures 4, 5 and 7, adipsin substantially promoted wound confraction (Figures 4, 5 and 7). In addition, adipsin increased epidermal closure from about 15 % to about 30 %, and increased keratinocytes migration from about 30 % to about 65 %, as compared with the buffer confrol (Figure 6).
These results demonstrate that an adipokine, such as adipsin, can effectively induce or accelerate wound healing.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents, patent applications and sequences identified by their name and/or database accession numbers mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent, patent application or sequence was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.
REFERENCES CITED BY NUMERALS (Additional references are cited in the text)
1. Hennings, H., Michael, D., Cheng, C, Steinert, P., Holbrook, K., and Yuspa, S.H. Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell, 19: 245-254, 1980.
2. Yuspa, S.H., Kilkenny, A.E., Steinert, P.M., and Roop, D.R. Expression of murine epidermal differentiation markers is tightly regulated by restricted exfracellular calcium concentrations in vitro. J.Cell Biol., 109: 1207-1217, 1989.
3. Fuchs, E. Epidermal differentiation: the bare essentials. J.Cell Biol., 77: 2807-2814, 1990.
4. Yuspa, S.H. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcmogenesis--TMrty-third G.H.A. Clowes Memorial Award Lecture. Cancer Res., 54: 1178- 1189, 1994.
5. Hennings, H. and Holbrook, K.A. Calcium regulation of cell-cell contact and differentiation of epidermal cells in culture. An ulfrastructural study. Exp.Cell Res., 143: 127-142, 1983.
6. Tennenbaum, T., Li, L., Belanger, A.J., De Luca, L.M., and Yuspa, S.H. Selective changes in laminin adhesion and α6β4 integrin regulation are associated with the initial steps in keratinocyte maturation. Cell Growth Differ., 7: 615-628, 1996.
7. Tennenbaum, T., Belanger, A.J., Quaranta, V., and Yuspa, S.H. Differential regulation of integrins and exfracellular matrix binding in epidermal differentiation and squamous tumor progression. J.InvestDermatol., 7: 157-161, 1996. 8. Weinstein, MX. Update on wound healing: a review of the literature. MiLMed., 163: 620-624, 1998.
9. Singer, A.J. and Clark, R.A. Cutaneous wound healing. N.Engl.J.Med., 341: 738-746, 1999.
10. Whitby, D.J. and Ferguson, M.W. Immunohistochemical localization of growth factors in fetal wound healing. Dev.Biol., 147: 207-215, 1991.
11. Kiritsy, C.P., Lynch, .B., and Lynch, S.E. Role of growth factors in cutaneous wound healing: a review. Crit.Rev.Oral Biol.Med., 4: 729-760, 1993.

Claims

WHAT IS CLAIMED IS:
1. A method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an adipokine, thereby inducing or accelerating the healing process of the skin wound.
2. The method of claim 1, wherein said adipokine is selected from the group consisting of adipsin, adiponectin, resistin, leptin, lipoprotein lipase, angiotensinogen, angiotesin-like 4, 1 -Butyrylglycerol, matrix metalloproteinase 2, matrix metalloproteinase 9, vascular endothelial growth factor, interleukin 6, and tumor necrosis factor α.
3. The method of claim 2, wherein said adipokine is adipsin.
4. The method of claim 1, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
5. The method of claim 1, wherein said adipokine is contained in a pharmaceutical composition adapted for topical application.
6. The method of claim 5, wherein said pharmaceutical composition is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
7. The method of claim 5, wherein said pharmaceutical composition includes a solid support.
8. A method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an agent capable of modulating expression and/or secretion of an adipokine from adipocytes, thereby inducing or accelerating the healing process of said skin wound.
9. The method of claim 8, wherein said adipokine is selected from the group consisting of adipsin, adiponectin, resistin, leptin, lipo protein lipase, angiotensinogen, angiotesin-like 4, 1 -Butyrylglycerol, matrix metalloproteinase 2, matrix metalloproteinase 9, and tumour neorosis factor α.
10. The method of claim 9, wherein said adipokine is adipsin.
11. The method of claim 8, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
12. The method of claim 8, wherein said agent is contained in a pharmaceutical composition adapted for topical application.
13. The method of claim 12, wherein said pharmaceutical composition is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
14 The method of claim 12, wherein said pharmaceutical composition includes a solid support.
15. A method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an agent capable of modulating differentiation of adipocytes, thereby inducing or accelerating the healing process of the skin wound.
16. The method of claim 15, wherein said agent is a PP AR regulator.
17. The method of claim 16, wherein said PPAR regulator is a PPAR-γ antagonist.
18. The method of claim 16, wherein said PPAR-γ antagonist is GW9662.
19. The method of claim 15, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
20. The method of claim 15, wherein said agent is contained in a pharmaceutical composition adapted for topical application.
21. The method of claim 20, wherein said pharmaceutical composition is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
22. The method of claim 20, wherein said pharmaceutical composition includes a solid support.
23. A method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an agent capable of attracting adipocytes to said skin wound, thereby inducing or accelerating the healing process of the skin wound.
24. The method of claim 23, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
25. The method of claim 23, wherein said agent is contained in a pharmaceutical composition adapted for topical application.
26. The method of claim 25, wherein said pharmaceutical composition is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
27. The method of claim 25, wherein said pharmaceutical composition includes a solid support.
28. A method of inducing or accelerating a healing process of a skin wound, comprising administering to the skin wound a therapeutically effective amount of an agent capable of enhancing proliferation of adipocytes in said skin wound, thereby inducing or accelerating the healing process of the skin wound.
29. The method of claim 28, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
30. The method of claim 28, wherein said agent is contained in a pharmaceutical composition adapted for topical application.
31. The method of claim 25, wherein said pharmaceutical composition is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
32. The method of claim 25, wherein said pharmaceutical composition includes a solid support.
33. A method of inducing or accelerating a healing process of a skin wound, comprising implanting into the skin wound a therapeutically effective amount of adipocytes, so as to induce or accelerate the healing process of the skin wound.
34. The method of claim 33, wherein said adipocytes are human adipocytes.
35. The method of claim 34, wherein said human adipocytes are autologous human adipocytes.
36. The method of claim 33, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
37. The method of claim 33, further comprising modulating expression and/or secretion of an adipokine by said adipocytes.
38. The method of claim 37, wherein said modulating is effected by modulating differentiation of said adipocytes.
39. The method of 38, wherein said modulating is effected by exposing said adipocytes to a PPAR regulator.
40. The method of 38, wherein said PPAR regulator is a PPAR-γ antagonist.
41. The method of 40, wherein said PPAR-γ antagonist is GW9662.
42. A method of inducing or accelerating a healing process of a skin wound, comprising implanting into the skin wound a therapeutically effective amount of preadipocytes, thereby inducing or accelerating the healing process of said skin wound.
43. The method of claim 42, further comprising promoting differentiation of said preadipocytes implanted in said skin wound.
44. The method of claim 43, wherein said promoting is effected by exposing said preadiposite to a substance capable of enhancing differentiation of said preadipocytes.
45. The method of claim 42, wherein said preadipocytes are human preadipocytes.
46. The method of claim 45, wherein said human preadipocytes are autologous human preadipocytes.
47. The method of claim 42, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
48. A method of inducing or accelerating a healing process of a skin wound, comprising implanting into the skin wound a therapeutically effective amount of stem cells, thereby inducing or accelerating the healing process of said skin wound.
49. The method of claim 48, further comprising promoting differentiation of said stem cells implanted in said skin wound.
50. The method of claim 49, wherein said promoting is effected by exposing said stem cells to a substance capable of enhancing differentiation of said stem cells into adipocytes.
51. The method of claim 48, wherein said stem cells are human stem cells.
52. The method of claim 51 , wherein said human stem cells are autologous stem cells.
53. The method of claim 52, wherein said human stem cells are mesenchymal stem cells.
54. The method of claim 48, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
55. A method of inducing or accelerating a healing process of a skin wound, comprising fransforming cells of the skin wound to express and secrete an adipokine, thereby inducing or accelerating the healing process of the skin wound.
56. The method of claim 55, wherein said adipokine is selected from the group consisting of adipsin, adiponectin, resistin, leptin, lipo protein lipase, angiotensinogen, angiotesin-like 4, 1 -Butyrylglycerol, matrix metalloproteinase 2, matrix metalloproteinase 9, and tumour neorosis factor α.
57. The method of claim 56, wherein said adipokine is adipsin.
58. The method of claim 55, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.
59. A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an adipokine, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
60. The method of claim 59, wherein said adipokine is selected from the group consisting of adipsin, adiponectin, resistin, leptin, lipo protein lipase, angiotensinogen, angiotesin-like 4, 1 -Butyrylglycerol, matrix metalloproteinase 2, matrix metalloproteinase 9, and tumour neorosis factor α.
61. The method of claim 60, wherein said adipokine is adipsin.
62. The pharmaceutical composition of claim 59, wherein said carrier is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
63. The pharmaceutical composition of claim 62, wherein said pharmaceutical composition includes a solid support.
64. A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an agent capable of modulating expression and/or secretion of an adipokine from adipocytes, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
65. The pharmaceutical composition of claim 64, wherein said carrier is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
66. The pharmaceutical composition of claim 65, wherein said pharmaceutical composition includes a solid support.
67. A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an agent capable of modulating differentiation of adipocytes, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
68. The pharmaceutical composition of claim 67, wherein said agent is a PPAR regulator.
69. The pharmaceutical composition of claim 68, wherein said PPAR regulator is a PPAR-γ antagonist.
70. The pharmaceutical composition of claim 69, wherein said agent is a PPAR-γ antagonist is GW9662.
71. The pharmaceutical composition of claim 67, wherein said carrier is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
72. The pharmaceutical composition of claim 71, wherein said pharmaceutical composition includes a solid support.
73. A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an agent capable of attracting adipocytes to the skin wound, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
74. The pharmaceutical composition of claim 73, wherein said formulation is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
75. The pharmaceutical composition of claim 74, wherein said pharmaceutical composition includes a solid support.
76. A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of an agent capable of enhancing proliferation of adipocytes, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.
77. The pharmaceutical composition of claim 76, wherein said carrier is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.
78. The pharmaceutical composition of claim 77, wherein said pharmaceutical composition includes a solid support.
79. A method of determining a capacity of an adipokine or an adipocyte modulator to induce or accelerate a healing process of a wound, comprising administering the adipokine or the adipocyte modulator to the wound, and evaluating said wound for a keratinocytes migration and/or an epidermal closure, to thereby determine the capacity of said adipokine or said adipocyte modulator to induce or accelerate heating of wounds.
80. The method of claim 79, wherein said adipocyte modulator is an adipocyte differentiation modulator or an adipocyte activity modulator.
81. The method of claim 79, wherein said wound is an incision wound.
82. The method of claim 81, wherein said incision wound is effected in an experimental animal.
83. The method of claim 79, wherein said adminisfrating is effected in one or more concentrations.
84. The method of claim 79, wherein said administrating is effected in one or more applications.
PCT/IL2004/000727 2003-08-07 2004-08-05 Pharmaceutical compositions and methods for accelerating wound healing WO2005013885A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA2535029A CA2535029C (en) 2003-08-07 2004-08-05 Pharmaceutical compositions and methods for accelerating wound healing
NZ545086A NZ545086A (en) 2003-08-07 2004-08-05 Pharmaceutical compositions and methods for accelerating wound healing
ES04745067T ES2375565T3 (en) 2003-08-07 2004-08-05 PHARMACEUTICAL COMPOSITIONS AND METHODS TO ACCELERATE WOUND HEALING.
JP2006522494A JP4668902B2 (en) 2003-08-07 2004-08-05 Pharmaceutical composition and method for promoting wound healing
AT04745067T ATE529125T1 (en) 2003-08-07 2004-08-05 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ACCELERATING WOUND HEALING
CN200480029538XA CN101287483B (en) 2003-08-07 2004-08-05 Pharmaceutical compositions and methods for accelerating wound healing
EP04745067A EP1651161B1 (en) 2003-08-07 2004-08-05 Pharmaceutical compositions and methods for accelerating wound healing
DK04745067.1T DK1651161T3 (en) 2003-08-07 2004-08-05 Pharmaceutical compositions and methods for promoting wound healing
AU2004263009A AU2004263009B2 (en) 2003-08-07 2004-08-05 Pharmaceutical compositions and methods for accelerating wound healing
US11/348,527 US7638484B2 (en) 2003-08-07 2006-02-07 Methods for accelerating wound healing by administration of adipokines
IL173596A IL173596A0 (en) 2003-08-07 2006-02-07 Pharmaceutical compositions and methods for accelerating wound healing
HK06111955.4A HK1091400A1 (en) 2003-08-07 2006-10-31 Pharmaceutical compositions and methods for accelerating wound healing
US12/009,567 US20080159978A1 (en) 2003-08-07 2008-01-18 Methods for accelerating wound healing by administration of adipokines
US13/224,311 US8507431B2 (en) 2003-08-07 2011-09-01 Methods for accelerating wound healing by administration of a preadipocyte modulator or an adipocyte modulator
US13/924,929 US20140148389A1 (en) 2003-08-07 2013-06-24 Methods for accelerating wound healing by administration of adipokines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49300003P 2003-08-07 2003-08-07
US60/493,000 2003-08-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/348,527 Continuation-In-Part US7638484B2 (en) 2003-08-07 2006-02-07 Methods for accelerating wound healing by administration of adipokines
US11/384,527 Continuation-In-Part US7925957B2 (en) 2006-03-20 2006-03-20 Validating data using processor instructions

Publications (2)

Publication Number Publication Date
WO2005013885A2 true WO2005013885A2 (en) 2005-02-17
WO2005013885A3 WO2005013885A3 (en) 2008-05-02

Family

ID=34135191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/000727 WO2005013885A2 (en) 2003-08-07 2004-08-05 Pharmaceutical compositions and methods for accelerating wound healing

Country Status (14)

Country Link
US (4) US7638484B2 (en)
EP (1) EP1651161B1 (en)
JP (2) JP4668902B2 (en)
CN (2) CN102120031B (en)
AT (1) ATE529125T1 (en)
AU (1) AU2004263009B2 (en)
CA (1) CA2535029C (en)
DK (1) DK1651161T3 (en)
ES (1) ES2375565T3 (en)
HK (2) HK1091400A1 (en)
NZ (1) NZ545086A (en)
RU (2) RU2358753C2 (en)
WO (1) WO2005013885A2 (en)
ZA (1) ZA200601089B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682172A2 (en) * 2003-10-09 2006-07-26 Trustees Of Boston University Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis
JP2006230316A (en) * 2005-02-25 2006-09-07 Japan Health Science Foundation Cell having wound healing ability without scar and method for preparing the same
EP1940440A2 (en) * 2005-08-29 2008-07-09 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2185730A1 (en) * 2007-08-23 2010-05-19 Intrexon Corporation Methods and compositions for diagnosing disease
EP2298864A3 (en) * 2004-03-22 2011-11-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US8093211B2 (en) 2000-07-31 2012-01-10 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
EP2417972A2 (en) * 2009-04-06 2012-02-15 Neurotech Pharmaceuticals Co., Ltd. Pharmaceutical composition for treating or preventing burn injuries
WO2012122604A1 (en) * 2011-03-15 2012-09-20 Cell Ideas Pty Ltd Pharmaceutical compositions and topical use thereof
US8349793B2 (en) 2010-01-11 2013-01-08 Heal0r, Ltd. Method for treatment of inflammatory disease and disorder
AU2013203165B2 (en) * 2011-03-15 2015-02-26 Cell Ideas Pty Ltd Pharmaceutical compositions and topical use thereof
US9062288B2 (en) 2008-08-22 2015-06-23 Regeneus Ltd Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes
AU2015202776B2 (en) * 2011-03-15 2017-08-17 Cell Ideas Pty Ltd Pharmaceutical compositions and topical use thereof
US10159641B2 (en) 2014-03-31 2018-12-25 Lubrizol Advanced Materials, Inc. Ferment extract of a bacterial strain for the increase of adiponectin levels
US10206956B2 (en) 2012-06-26 2019-02-19 Rusty Property Holdings Pty Ltd. Compositions and methods for reducing frequency and/or severity of headache

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
DK1651161T3 (en) * 2003-08-07 2012-01-30 Healor Ltd Pharmaceutical compositions and methods for promoting wound healing
KR100888889B1 (en) 2007-07-24 2009-03-17 부산대학교 산학협력단 Pharmaceutical Composition for Angiogenesis Stimulation Comprising Visfatin As an Active Ingredient
US20100310542A1 (en) * 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
RU2573912C2 (en) 2008-10-08 2016-01-27 Интрексон Корпорейшн Constructed cells, expressing multiple immunomodulators, and thereof application
US8173154B2 (en) 2010-01-06 2012-05-08 The Curators Of The University Of Missouri Boron trioxide glass-based fibers and particles in dressings, sutures, surgical glue, and other wound care compositions
WO2012063237A2 (en) * 2010-11-08 2012-05-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
JP5812095B2 (en) * 2011-09-09 2015-11-11 コニカミノルタ株式会社 Biological substance detection method
JP6113981B2 (en) * 2012-06-29 2017-04-12 ポーラ化成工業株式会社 Screening method
KR101588394B1 (en) 2013-05-09 2016-01-25 라정찬 Media Composition for Improving Renewal Ability and Method for Culturing Stem Cells Using the Same
KR20160010212A (en) 2014-07-18 2016-01-27 주식회사 젬백스앤카엘 Anti-aging and wound-healing peptide and composition comprising the same
EP3090764A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Compositions comprising mesenchymal stem cells and uses thereof
CN107847558B (en) * 2015-07-31 2021-05-04 宝血纯化科技股份有限公司 Composition for promoting wound healing
US11458227B2 (en) * 2015-08-07 2022-10-04 The Johns Hopkins University Compositions and methods for modulating wound healing and regeneration
EP3132809A1 (en) 2015-08-21 2017-02-22 Bioskinco GmbH Composition and products comprising senescent cells for use in tissue regeneration
KR102469326B1 (en) * 2016-03-24 2022-11-23 스템랩, 에스에이 Utilization of cord blood-derived exosomes for tissue repair
CN106215172A (en) * 2016-07-28 2016-12-14 广州赛莱拉干细胞科技股份有限公司 Fat preparation for improving wound healing and preparation method thereof
CN106177919A (en) * 2016-07-28 2016-12-07 广州赛莱拉干细胞科技股份有限公司 Fat preparation for improving wound healing and preparation method thereof
US11278597B2 (en) 2017-03-17 2022-03-22 Rutgers, The State University Of New Jersey Compositions and methods for wound healing
RU2663907C1 (en) * 2017-05-04 2018-08-13 Ринат Маратович Урузбаев Method of accelerating healing of skin damage
CN113491696A (en) * 2017-07-05 2021-10-12 江阴优培尔康药业有限公司 Topical formulations comprising montelukast in combination with mussel adhesive protein
RU2687007C2 (en) * 2017-09-12 2019-05-06 Общество с ограниченной ответственностью "Клеточные Системы" Method for biotechnological skin recovery with human allogenic human stem cells
CN109876012B (en) * 2019-03-21 2022-01-11 北京隆祺生物科技有限公司 Medicinal composition and application thereof in promoting skin wound healing
CN113304174A (en) * 2020-03-30 2021-08-27 大树医疗美容科技(广州)有限公司 Culture solution extract secreted by human body fat cells
US20230137084A1 (en) * 2021-10-28 2023-05-04 Kismet Technologies Llc Nanoparticles to promote wound healing and antimicrobial infection control
CN118121578B (en) * 2024-05-06 2024-08-16 广州市朝利良生物科技有限公司 Compound EH-P008V and application thereof in preparation of wound healing promoting drugs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2001A (en) * 1841-03-12 Sawmill
US200A (en) * 1837-05-22 Geoege
GB280460A (en) 1927-06-10 1927-11-17 George Percival Milnes Improvements in mouthpieces for tobacco pipes and other tubes
US3549747A (en) 1968-02-20 1970-12-22 Flow Pharma Inc Contact lens wetting solution and method of using same
US3947573A (en) 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3856919A (en) 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3767788A (en) 1970-06-08 1973-10-23 Burton Parsons Chemicals Inc Ophthalmic solution
US3767789A (en) 1971-06-21 1973-10-23 Burton Parsons & Co Inc Method of providing a synthetic mucus in vivo
US3987163A (en) 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
US3907985A (en) 1973-07-27 1975-09-23 Burton Parsons And Company Inc Polystyrene sulfonate containing opthalmic solutions
US4029817A (en) 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US3920810A (en) 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US4120949A (en) 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4558033A (en) * 1983-06-06 1985-12-10 Amgen Potentiation of the effects of insulin by peptides
US4673649A (en) 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
AU4292585A (en) 1984-04-30 1985-11-28 Trustees Of Columbia University In The City Of New York, The Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
US5110801A (en) 1984-08-13 1992-05-05 Leveen Harry H Treatment of acne
US4843096A (en) 1985-06-26 1989-06-27 Stiefel Laboratories, Inc. Treatment of acne
EP0223977B1 (en) 1985-11-25 1990-10-10 Wako Pure Chemical Industries, Ltd. Colour developing method in clinical examinations
US4833257A (en) 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
JPH0739508B2 (en) * 1986-11-11 1995-05-01 株式会社林原生物化学研究所 Pullulan / polyethylene glycol aggregate, its production method and use
US4885163A (en) 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5700450A (en) 1988-03-30 1997-12-23 The Trustees Of Boston University Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof
ZA892928B (en) 1988-04-25 1991-01-30 Pro Neuron Inc Pharmaceutical compositions containing deoxyribonucleosides for wound healing
US5137734A (en) * 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5158935A (en) * 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
US5723119A (en) * 1989-07-28 1998-03-03 Schering Corporation Method for enhancing wound healing/repair with IL-4
US5145679A (en) 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5423778A (en) * 1989-12-14 1995-06-13 Elof Eriksson System and method for transplantation of cells
US5981606A (en) 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
JPH06503837A (en) 1991-04-11 1994-04-28 シェリング・コーポレーション Antitumor and antipsoriatic drugs
DE69229779T2 (en) 1991-04-19 1999-12-23 Lds Technologies, Inc. CONVERTIBLE MICROEMULSION CONNECTIONS
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
HUT67319A (en) 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
WO1993008825A1 (en) 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
DE4208552A1 (en) 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh TOPICAL MEDICINE FORMS WITH INSULIN
GB9210574D0 (en) * 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
DE69531712T2 (en) 1994-04-25 2004-07-01 Japan Science And Technology Corp., Kawaguchi Hybrid gel that secretes a biologically active substance
US6028118A (en) 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
JP3414539B2 (en) 1994-05-11 2003-06-09 有限会社ドット Composition for nasal absorption
RU2198900C2 (en) 1994-05-24 2003-02-20 Еда Рисерч энд Дивелопмент Ко., Лтд. Improved copolymer-1 and method of preparation thereof
JP4624495B2 (en) 1994-12-29 2011-02-02 フェリング・インターナショナル・センター・エス．・エー． Production of human insulin
AUPN089295A0 (en) 1995-02-02 1995-03-02 International Diabetes Institute Treatment of diabetic neuropathy
US5631245A (en) * 1995-06-06 1997-05-20 Biodynamics Pharmaceuticals, Inc. Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
CA2244222A1 (en) 1996-01-23 1997-07-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and rna molecules
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
JPH10158188A (en) 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd Composition for treating cornea
GB9702943D0 (en) 1997-02-13 1997-04-02 Univ Manchester Wound healing
CN1275897A (en) 1997-10-16 2000-12-06 朱德广 Novel powerful cosmetic or pharmaceutical composition
AU3635099A (en) 1997-12-15 1999-07-26 Beth Israel Deaconess Medical Center Methods and reagents for modulating cell motility
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
FR2773075B1 (en) 1997-12-31 2000-05-05 Cird Galderma USE OF PPAR-GAMMA ACTIVATORS IN DERMATOLOGY
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US6790207B2 (en) 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6489306B2 (en) 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
US6335201B1 (en) 1998-03-06 2002-01-01 The Regents Of The University Of California Method and apparatus for detecting enzymatic activity using molecules that change electrophoretic mobility
CN1379681A (en) * 1998-04-17 2002-11-13 安乔格尼克斯公司 therapeutic angiogenic factors and methods for their use
AU4672199A (en) * 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2327301T3 (en) 1998-09-25 2009-10-27 Yeda Research And Development Co., Ltd. POLYPEPTIDES RELATED TO COPOLIMERO 1 FOR USE AS MOLECULAR WEIGHT MARKERS AND THERAPEUTIC USE.
US6096288A (en) 1998-10-12 2000-08-01 Mobil Oil Corporation Synthesis of the cubic mesoporous molecular sieve MCM-48
CA2350599A1 (en) 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
BR0009772A (en) 1999-04-14 2002-01-08 Us Health Compositions containing immunotoxins and agents that inhibit the maturation of dendritic cells to induce immune tolerance to a graft
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6541447B1 (en) 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
DE60127656T2 (en) 2000-02-25 2007-12-20 Immunex Corp., Seattle INTEGRIN ANTAGONISTS
CN100398153C (en) 2000-03-24 2008-07-02 诺瓦提斯公司 Improved treatment of neovascularization
AU2001251136A1 (en) 2000-04-06 2001-10-23 University Technology Corporation Compositions and methods for promoting wound healing
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20100129332A1 (en) 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US6673603B2 (en) 2000-09-01 2004-01-06 Modex Therapeutiques, S.A. Cell paste comprising keratinocytes and fibroblasts
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
US20020119914A1 (en) 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
JP2002198443A (en) 2000-12-26 2002-07-12 Nec Corp Semiconductor device and its fabricating method
GB0103877D0 (en) 2001-02-16 2001-04-04 King S College London Novel Drug Delivery system
DE10109280A1 (en) 2001-02-26 2002-09-05 Peter Mayser Indole derivatives with inhibitory effects on protein kinases
ATE409037T1 (en) * 2001-03-08 2008-10-15 Univ Kentucky Res Found METHOD FOR INCREASE LEPTIN LEVELS USING NICOTINIC ACID COMPOUNDS
KR100404072B1 (en) 2001-03-12 2003-11-03 주식회사 두산 Therapeutic composition for broad spectrum dermal disease
JP2002272831A (en) 2001-03-14 2002-09-24 Fumio Kamiyama Wound coating tacky adhesive sheet
JP2004532230A (en) 2001-04-30 2004-10-21 アラクノーバ・セラピューティックス・リミテッド Treatment of scarring and related conditions using PPAR-gamma activator
AU2002319847A1 (en) 2001-05-23 2002-12-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) New nuclear receptor cofactors and related modulators
ES2184623B1 (en) 2001-06-29 2004-09-16 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (C.I.E.M.A.T.) ARTIFICIAL SKIN AUTOLOGA SECRETORA DE LEPTINA AND METHOD OF OBTAINING.
US20030124503A1 (en) 2001-12-28 2003-07-03 Olivencia-Yurvati Albert H. Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
US6967018B2 (en) * 2002-01-11 2005-11-22 Applied Genetic Technologies Corporation Adiponectin gene therapy
RU2249467C2 (en) 2002-11-25 2005-04-10 ООО Научно-производственное предприятие "ЭРЛОН", Лтд. Medicinal material and products based upon this material
US20040175384A1 (en) 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
SE0300207D0 (en) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
NZ588743A (en) * 2003-07-15 2012-05-25 Univ Bar Ilan Use of a protein kinase C (PKC) alpha inhibitor for treating inflammation of the skin
EP1646383A4 (en) 2003-07-21 2009-03-25 Bethesda Pharmaceuticals Inc Design and synthesis of optimized ligands for ppar
DK1651161T3 (en) 2003-08-07 2012-01-30 Healor Ltd Pharmaceutical compositions and methods for promoting wound healing
CA2539132A1 (en) 2003-09-16 2005-03-24 Garvan Institute Of Medical Research Methods for identifying modulators of protein kinase c-epsilon (pkc.epsilon.) and method of treatment of aberrant glucose metabolism associated therewith
EP1702214A4 (en) 2003-12-24 2007-12-19 Wyeth Corp Methods of treating asthma
WO2006086681A2 (en) 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
WO2006108270A1 (en) 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
CA2659961A1 (en) 2005-08-05 2007-02-15 Pharmagap Inc. Targeted protein kinase c inhibitors and uses thereof
WO2007026356A2 (en) 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US20090306045A1 (en) 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
US20080292726A1 (en) 2007-01-23 2008-11-27 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
US20100310542A1 (en) 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
RU2011111728A (en) 2008-08-29 2012-10-10 Топотаргет А/С (Dk) NEW DERIVATIVES OF UREA AND THIRE UREA
EP2323637A1 (en) 2008-09-09 2011-05-25 University of East Anglia Treatment of fibrotic eye disorders
CN103800903A (en) 2009-02-24 2014-05-21 希尔洛有限公司 Visfatin therapeutic agents for the treatment of acne and other conditions
AU2011204425A1 (en) 2010-01-11 2012-08-02 Healor Ltd. Method for treatment of inflammatory disease and disorder

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", vol. I-III, 1994
"Genome Analysis: A Laboratory Manual Series", vol. 1-4, 1998, COLD SPRING HARBOR LABORATORY PRESS
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1989, JOHN WILEY AND SONS
FRANK ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 106, no. 4, August 2000 (2000-08-01), pages 501 - 509
MICHALNIK ET AL., J. CELL BIOL., vol. 154, 2001, pages 799 - 814
PERBAL: "A Practical Guide to Molecular Cloning", 1988, JOHN WILEY & SONS
RANGWALA; LAZAR, ANN. REV. NUTT., vol. 20, 2000, pages 535 - 539
S. ROMANO DI PEPPE ET AL., GENE THERAPY, vol. 9, 2002, pages 1271 - 1277
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989
WABLI W.; SWISS, MED. WKLY., vol. 132, 2002, pages 83 - 91
WATSON ET AL.: "Recombinant DNA", SCIENTIFIC AMERICAN BOOKS

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093211B2 (en) 2000-07-31 2012-01-10 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
EP1682172A2 (en) * 2003-10-09 2006-07-26 Trustees Of Boston University Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis
EP1682172A4 (en) * 2003-10-09 2009-08-12 Univ Boston Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis
US10960025B2 (en) 2004-03-22 2021-03-30 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US11389484B2 (en) 2004-03-22 2022-07-19 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10828334B1 (en) 2004-03-22 2020-11-10 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10729727B2 (en) 2004-03-22 2020-08-04 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10716814B2 (en) 2004-03-22 2020-07-21 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
EP2298864A3 (en) * 2004-03-22 2011-11-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US10668101B2 (en) 2004-03-22 2020-06-02 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US9943547B2 (en) 2004-03-22 2018-04-17 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US9694035B2 (en) 2004-03-22 2017-07-04 Mesoblast International Sarl Mesenchymal stem cells and uses therefor
JP2006230316A (en) * 2005-02-25 2006-09-07 Japan Health Science Foundation Cell having wound healing ability without scar and method for preparing the same
EP2462944A3 (en) * 2005-08-29 2012-09-12 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
JP2009506107A (en) * 2005-08-29 2009-02-12 ヒールオア・リミテッド Methods and compositions for preventing and treating diabetes and skin aging
EP2462944A2 (en) 2005-08-29 2012-06-13 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2452687A2 (en) 2005-08-29 2012-05-16 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2452691A3 (en) * 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention of diabetic and aged skin
EP2452686A3 (en) * 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2452687A3 (en) * 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2452686A2 (en) 2005-08-29 2012-05-16 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2452691A2 (en) 2005-08-29 2012-05-16 HealOr Ltd. Methods and compositions for prevention of diabetic and aged skin
EP1940440A4 (en) * 2005-08-29 2009-11-11 Healor Ltd Methods and compositions for prevention and treatment of diabetic and aged skin
US8367606B2 (en) 2005-08-29 2013-02-05 Healor Ltd. Method and compositions for prevention and treatment of diabetic and aged skin
EP1940440A2 (en) * 2005-08-29 2008-07-09 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2185730A1 (en) * 2007-08-23 2010-05-19 Intrexon Corporation Methods and compositions for diagnosing disease
EP2185730A4 (en) * 2007-08-23 2010-10-27 Intrexon Corp Methods and compositions for diagnosing disease
US9062288B2 (en) 2008-08-22 2015-06-23 Regeneus Ltd Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes
CN102421430B (en) * 2009-04-06 2014-06-25 纽若泰克制药株式会社 Pharmaceutical composition for treating or preventing burn injuries
CN102421430A (en) * 2009-04-06 2012-04-18 纽若泰克制药株式会社 Pharmaceutical composition for treating or preventing burn injuries
EP2417972A4 (en) * 2009-04-06 2012-08-22 Neurotech Pharmaceuticals Co Ltd Pharmaceutical composition for treating or preventing burn injuries
EP2417972A2 (en) * 2009-04-06 2012-02-15 Neurotech Pharmaceuticals Co., Ltd. Pharmaceutical composition for treating or preventing burn injuries
US8349793B2 (en) 2010-01-11 2013-01-08 Heal0r, Ltd. Method for treatment of inflammatory disease and disorder
WO2012122604A1 (en) * 2011-03-15 2012-09-20 Cell Ideas Pty Ltd Pharmaceutical compositions and topical use thereof
AU2015202776B2 (en) * 2011-03-15 2017-08-17 Cell Ideas Pty Ltd Pharmaceutical compositions and topical use thereof
US9730964B2 (en) 2011-03-15 2017-08-15 Cell Ideas Pty Ltd. Pharmaceutical compositions and topical use thereof
EP3156060A1 (en) * 2011-03-15 2017-04-19 Cell Ideas Pty Ltd. Pharmaceutical compositions and topical use thereof
AU2013203165B2 (en) * 2011-03-15 2015-02-26 Cell Ideas Pty Ltd Pharmaceutical compositions and topical use thereof
AU2012229890B2 (en) * 2011-03-15 2015-02-26 Cell Ideas Pty Ltd Pharmaceutical compositions and topical use thereof
US10967008B2 (en) 2011-03-15 2021-04-06 Cell Ideas Pty Ltd Pharmaceutical compositions and topical use thereof
US20140087001A1 (en) * 2011-03-15 2014-03-27 Graham Vesey Pharmaceutical Compositions and Topical Use Thereof
US10206956B2 (en) 2012-06-26 2019-02-19 Rusty Property Holdings Pty Ltd. Compositions and methods for reducing frequency and/or severity of headache
US10159641B2 (en) 2014-03-31 2018-12-25 Lubrizol Advanced Materials, Inc. Ferment extract of a bacterial strain for the increase of adiponectin levels

Also Published As

Publication number Publication date
HK1091400A1 (en) 2007-01-19
JP2011068663A (en) 2011-04-07
ZA200601089B (en) 2007-05-30
DK1651161T3 (en) 2012-01-30
US20120020917A1 (en) 2012-01-26
EP1651161A2 (en) 2006-05-03
US8507431B2 (en) 2013-08-13
RU2419441C2 (en) 2011-05-27
US20060177418A1 (en) 2006-08-10
EP1651161B1 (en) 2011-10-19
CN101287483A (en) 2008-10-15
CN102120031A (en) 2011-07-13
JP4668902B2 (en) 2011-04-13
JP2007512226A (en) 2007-05-17
AU2004263009B2 (en) 2009-12-24
AU2004263009A1 (en) 2005-02-17
HK1156515A1 (en) 2012-06-15
US20080159978A1 (en) 2008-07-03
US7638484B2 (en) 2009-12-29
NZ545086A (en) 2011-06-30
CA2535029C (en) 2013-07-16
EP1651161A4 (en) 2009-09-09
ES2375565T3 (en) 2012-03-02
US20140148389A1 (en) 2014-05-29
RU2358753C2 (en) 2009-06-20
ATE529125T1 (en) 2011-11-15
WO2005013885A3 (en) 2008-05-02
RU2009103919A (en) 2010-08-20
CA2535029A1 (en) 2005-02-17
CN101287483B (en) 2012-02-29
CN102120031B (en) 2012-12-05
RU2006106909A (en) 2006-09-10

Similar Documents

Publication Publication Date Title
AU2004263009B2 (en) Pharmaceutical compositions and methods for accelerating wound healing
JP5852051B2 (en) Methods and pharmaceutical compositions for wound healing
JP5385321B2 (en) Methods and pharmaceutical compositions for wound treatment
US20060258562A1 (en) Methods and pharmaceutical compositions for healing wounds
JP2011057711A (en) Method and pharmaceutical composition for healing wound
KR20200049676A (en) Pharmaceutical composition for preventing or treating tendinopathy comprising isolated mitochondria
AU2011226776B2 (en) Methods and pharmaceutical compositions for healing wounds
US20160175364A1 (en) Trophoblast derived microparticles for treating ischemic tissue and wounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480029538.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 545086

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2535029

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 608/DELNP/2006

Country of ref document: IN

Ref document number: 2006522494

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 173596

Country of ref document: IL

Ref document number: 11348527

Country of ref document: US

Ref document number: 200601089

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004263009

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004745067

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006106909

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2004263009

Country of ref document: AU

Date of ref document: 20040805

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004263009

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004745067

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11348527

Country of ref document: US